Astrazeneca PLC 6-K, filed Nov 12, 2024
Astrazeneca PLC (AZN)
6-K
2024-11-12
For: 2024-11-12
View Original
Added on
July 04, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on November 12, 2024.
|
|
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
9M and Q3 2024 Results
AstraZeneca
12 November 2024
9M and Q3 2024 results
Upgrade to full year 2024 guidance underpinned by strong underlying
growth momentum
Revenue and EPS summary
|
|
|
9M 2024
|
% Change
|
Q3 2024
|
% Change
|
||
|
|
|
$m
|
Actual
|
CER[1]
|
$m
|
Actual
|
CER
|
|
- Product Sales
|
|
37,576
|
16
|
19
|
12,947
|
18
|
20
|
|
-
Alliance Revenue
|
|
1,498
|
49
|
50
|
559
|
48
|
50
|
|
-
Collaboration Revenue
|
|
108
|
(66)
|
(66)
|
59
|
(39)
|
(40)
|
|
Total
Revenue
|
|
39,182
|
16
|
19
|
13,565
|
18
|
21
|
|
Reported
EPS
|
|
$3.57
|
11
|
21
|
$0.92
|
4
|
17
|
|
Core[2] EPS
|
|
$6.12
|
5
|
11
|
$2.08
|
20
|
27
|
Financial performance for 9M
2024 (Growth numbers at constant exchange
rates)
‒ Total
Revenue up 19% to $39,182m, driven by a 19% increase in Product
Sales and continued growth in Alliance Revenue from partnered
medicines
‒ Total
Revenue growth from Oncology was 22%, CVRM 21%, R&I 24% and
Rare Disease 14%
‒ Core
Product Sales Gross Margin[3] of
82%
‒ Core
Operating Margin of 32%
‒ Core
Tax Rate of 20%
‒ Core
EPS increased 11% to $6.12. In the prior year period, Core EPS
included gains totalling $953m from the disposal
of Pulmicort
Flexhaler US rights and
updated contractual arrangements for Beyfortus
‒ Guidance
for FY 2024 Total Revenue and Core EPS growth at CER upgraded to
high teens percentage growth
Pascal Soriot, Chief Executive Officer, AstraZeneca,
said:
"Our company has continued on its strong growth trajectory in the
first nine months of 2024. Total Revenue and Core EPS were up 21%
and 27% respectively in the third quarter, reflecting the
increasing demand for our medicines across Oncology,
BioPharmaceuticals and Rare Disease and supporting an upgrade to
our full year 2024 guidance.
In the year to date we have announced the results for multiple
positive high-value trials and are working to bring these new
options to patients as quickly as possible. Additionally, the
quality and impact of our scientific research was well recognised
this quarter with data for AstraZeneca medicines featuring in an
unprecedented five Presidential Plenary sessions at the two major
oncology conferences in September.
We are highly encouraged by the broad-based underlying momentum we
are seeing across our company in 2024, and growth looks set to
continue through 2025, providing a solid foundation to deliver on
our 2030 ambition.
Finally, we take the matters in China very seriously. If requested
we will fully cooperate with the authorities. We remain committed
to delivering innovative life-changing medicines to patients in
China."
Key milestones achieved since the prior results
announcement
‒ Positive
read-outs for Tagrisso plus Orpathys in EGFRm NSCLC with high levels of MET
overexpression and/or
amplification (SAVANNAH), Calquence in combination with venetoclax, with or
without obinutuzumab in previously untreated CLL (AMPLIFY), and the
next generation propellant for Breztri. Koselugo in adult patients with NF1-PN
(KOMET), Tezspire in severe chronic rhinosinusitis with nasal
polyps (WAYPOINT)
‒ US
approvals for Tagrisso in unresectable, Stage
III EGFRm NSCLC (LAURA) and Imfinzi plus chemotherapy in resectable early-stage
NSCLC (AEGEAN) and FluMist for self-administration. EU approvals
for Imfinzi plus chemotherapy followed
by Imfinzi alone in mismatch repair deficient
endometrial cancer (DUO-E), Imfinzi plus chemotherapy followed
by Lynparza and Imfinzi in mismatch repair proficient endometrial
cancer (DUO-E) and Fasenra for EGPA (MANDARA). China approvals
for Enhertu in unresectable, locally advanced or
metastatic HER2-mutated NSCLC (DESTINY-Lung02,
DESTINY-Lung05), Enhertu in locally advanced or metastatic
HER2-positive gastric or gastroesophageal junction adenocarcinoma
(DESTINY-Gastric06), and Fasenra for severe eosinophilic asthma
(MIRACLE)
Guidance
Given the strength of underlying Product Sales and Alliance
Revenue, as well as increased confidence in achieving certain
sales-based milestones, the Company raises its Total Revenue and
Core EPS guidance for FY 2024 at CER.
Total Revenue is expected to increase by a high teens percentage
(previously a mid teens percentage)
Core EPS is expected to increase by a high teens percentage
(previously a mid teens percentage)
‒ Other
elements of the Income Statement are expected to be broadly in-line
with the indications issued in the Company's H1 2024 earnings
statement
The Company is unable to provide guidance on a Reported basis
because it cannot reliably forecast material elements of the
Reported results, including any fair value adjustments arising on
acquisition-related liabilities, intangible asset impairment
charges and legal settlement provisions. Please refer to the
cautionary statements section regarding forward-looking statements
at the end of this announcement.
Currency impact
If foreign exchange rates for October 2024 to December 2024 were to
remain at the average rates seen in September 2024, it is
anticipated that FY 2024 Total Revenue would incur a low
single-digit percentage adverse impact compared to the performance
at CER (unchanged from previous guidance), and Core EPS would incur
a mid single-digit percentage adverse impact (unchanged from
previous guidance). The Company's foreign exchange rate sensitivity
analysis is provided in Table 17.
China
As previously disclosed, the Company is aware of a number of
individual investigations by the Chinese authorities into current
and former AstraZeneca employees. To the best of the Company's
knowledge, the investigations include allegations of medical
insurance fraud, illegal drug importation and personal information
breaches. Recently Leon Wang, EVP International and AstraZeneca
China President was detained. The Company has not received any
notification that it is itself under investigation. If requested,
AstraZeneca will fully cooperate with the Chinese
authorities.
Table 1: Key
elements of Total Revenue performance in Q3
2024
|
|
% Change
|
|
|
|
||||||
|
Revenue type
|
|
$m
|
Actual %
|
CER %
|
|
|
||||
|
Product Sales
|
|
12,947
|
18
|
20
|
|
|
||||
|
Alliance Revenue
|
|
559
|
48
|
50
|
|
∗ $49m Beyfortus (Q3 2023:
$17m)
∗ $361m Enhertu (Q3 2023:
$266m)
∗ $123m Tezspire (Q3 2023:
$74m)
|
||||
|
Collaboration Revenue
|
|
59
|
(39)
|
(40)
|
|
∗ $56m Beyfortus (Q3 2023:
$71m)
|
||||
|
Total Revenue
|
|
13,565
|
18
|
21
|
|
|
||||
|
Therapy areas
|
|
$m
|
Actual %
|
CER %
|
|
|
||||
|
Oncology
|
|
5,569
|
19
|
22
|
|
∗ Tagrisso up 14% (17% at
CER), Calquence up 24% (25% at
CER), Enhertu Total Revenue up 50% (55%
at CER)
|
||||
|
CVRM
|
|
3,159
|
18
|
20
|
|
∗ Farxiga up 25% (27% at
CER), Lokelma up 40% (42% at
CER)
|
||||
|
R&I
|
|
1,959
|
26
|
29
|
|
∗ Breztri up 56% (57% at
CER). Saphnelo up
63% (64% at CER), Tezspire up
>2x, Symbicort up 27% (31%
CER)
|
||||
|
V&I
|
|
460
|
48
|
49
|
|
∗ Beyfortus Total Revenue up 73%
(72% at CER), FluMist up 34% (31% at
CER)
|
||||
|
Rare Disease
|
|
2,148
|
9
|
11
|
|
● Ultomiris
up 33% (35% at CER), partially offset by decline in Soliris of 22%
(18% at CER), Strensiq up 20% (21% at CER) and Koselugo up 37% (39%
at CER)
|
||||
|
Other Medicines
|
|
270
|
(12)
|
(8)
|
|
|
||||
|
Total Revenue
|
|
13,565
|
18
|
21
|
|
|
||||
|
Regions
|
|
$m
|
Actual %
|
CER %
|
|
|
||||
|
US
|
|
6,008
|
23
|
23
|
|
|
||||
|
Emerging Markets
|
|
3,423
|
15
|
23
|
|
|
||||
|
- China
|
|
1,671
|
15
|
15
|
|
|
||||
|
- Ex-China Emerging Markets
|
|
1,752
|
16
|
31
|
|
|
||||
|
Europe
|
|
2,875
|
22
|
22
|
|
|
||||
|
Established RoW
|
|
1,260
|
(1)
|
4
|
|
|
||||
|
Total Revenue
|
|
13,565
|
18
|
21
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
Key alliance medicines
‒ Combined
sales of Enhertu, recorded by Daiichi Sankyo Company Limited
(Daiichi Sankyo) and AstraZeneca, amounted to $2,729m in 9M 2024
(9M 2023: $1,844m).
‒ Combined
sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to
$843m in 9M 2024 (9M 2023: $438m).
Table 2: Key
elements of financial performance in Q3 2024
|
Metric
|
Reported
|
Reported change
|
Core
|
Corechange
|
|
Comments[4]
|
|
Total Revenue
|
$13,565m
|
18% Actual 21% CER
|
$13,565m
|
18% Actual 21% CER
|
|
∗ See Table 1 and the Total Revenue section of this
document for further details
|
|
Product Sales Gross Margin
|
76%
|
-5pp Actual -4pp CER
|
81%
|
Stable Actual and CER
|
|
∗ Variations in Product Sales Gross Margin can be
expected between periods, due to product seasonality
(e.g. FluMist and Beyfortus sales are weighted to the second half of the
year), foreign exchange fluctuations and other
effects
‒ Reported
Product Sales Gross Margin impacted by PAAGR[5] inventory
related restructuring charges taken in the
quarter
|
|
R&D
expense
|
$3,115m
|
21% Actual 21% CER
|
$3,068m
|
23% Actual 24% CER
|
|
+
Increased investment in the pipeline
∗ Core R&D-to-Total Revenue ratio of 23%(Q3
2023: 22%)
|
|
SG&A expense
|
$5,143m
|
7% Actual 8% CER
|
$3,605m
|
8% Actual 9% CER
|
|
+
Market development for recent launches and pre-launch
activities
∗ Core SG&A-to-Total Revenue ratio of 27%(Q3
2023: 29%)
|
|
Other operating income and expense[6]
|
$25m
|
-65% Actual -61% CER
|
$24m
|
-65% Actual -61% CER
|
|
|
|
Operating Margin
|
16%
|
-1pp Actual Stable CER
|
32%
|
+1pp Actual +2pp CER
|
|
∗ See commentary above on Gross Margin, R&D,
SG&A and Other operating income and expense
|
|
Net finance expense
|
$274m
|
-6% Actual -15% CER
|
$329m
|
46% Actual 35% CER
|
|
+
New debt issued at higher interest rates
+
Higher level of Net debt
|
|
Tax rate
|
22%
|
+5pp Actual +5pp CER
|
19%
|
Stable Actual and CER
|
|
∗ Variations in the tax rate can
be expected between periods
|
|
EPS
|
$0.92
|
4% Actual 17% CER
|
$2.08
|
20% Actual 27% CER
|
|
∗ Further details of differences between Reported
and Core are shown in Table 12
|
Table 3:
Pipeline highlights since prior results
announcement
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
|
Regulatory approvals and other regulatory actions
|
Tagrisso
|
Unresectable, Stage III EGFRm NSCLC (LAURA)
|
Regulatory approval (US)
|
|
Imfinzi
|
Primary advanced or recurrent endometrial cancer with mismatch
repair deficiency (DUO-E)
|
Regulatory approval (EU)
|
|
|
Imfinzi + Lynparza
|
Primary advanced or recurrent endometrial cancer with mismatch
repair proficiency (DUO-E)
|
Regulatory approval (EU)
|
|
|
Imfinzi
|
Resectable early-stage (IIA-IIIB) NSCLC (AEGEAN)
|
Regulatory approval (US)
|
|
|
Enhertu
|
Locally advanced or metastatic HER2-positive gastric or
gastroesophageal junction adenocarcinoma
(DESTINY-Gastric06)
|
Regulatory approval (CN)
|
|
|
Enhertu
|
Unresectable locally advanced or
metastatic HER2m
NSCLC (DESTINY-Lung02, DESTINY-Lung05)
|
Regulatory approval (CN)
|
|
|
Fasenra
|
EGPA (MANDARA)
|
Regulatory approval (US, EU)
|
|
|
Fasenra
|
Fasenra (MIRACLE)
|
Regulatory approval (CN)
|
|
|
FluMist
|
Self-administration
|
Regulatory approval (US)
|
|
|
Regulatory submissionsor acceptances*
|
Tagrisso
|
EGFRm NSCLC (Stage
III
unresectable) (LAURA)
|
Regulatory submission (EU, JP, CN)
|
|
Imfinzi
|
Muscle-invasive bladder
Cancer (NIAGARA)
|
Regulatory submission (EU)
|
|
|
Imfinzi
|
NSCLC (neoadjuvant) AEGEAN
|
Regulatory submission (JP)
|
|
|
Imfinzi
|
SCLC (limited stage) (ADRIATIC)
|
Regulatory submission (US, EU, JP, CN)
|
|
|
Calquence
|
Mantle cell lymphoma (1st-line) (ECHO)
|
Regulatory submission (US, EU, JP)
|
|
|
Calquence
|
CLL (ELEVATE-TN)
|
Regulatory submission (CN)
|
|
|
Lynparza
|
mCRPC (PROpel)
|
Regulatory submission (CN)
|
|
|
Enhertu
|
HER2-low breast cancer
(2nd-line) (DESTINY-Breast06)
|
Regulatory submission (US, EU, JP)
|
|
|
Wainua
|
Hereditary transthyretin-mediated amyloid polyneuropathy
(NEURO-TTRansform)
|
Regulatory submission (CN)
|
|
|
Breztri and
HFO1234ze
|
Moderate to severe COPD
|
Regulatory submission (EU)
|
|
|
Sipavibart
|
Prevention of COVID-19
(SUPERNOVA)
|
Regulatory submission (JP)
|
|
|
Ultomiris
|
NMOSD (CHAMPION-NMOSD)
|
Regulatory submission (CN)
|
|
|
Phase III / registrational data readouts and other
developments
|
Tagrisso + Orpathys
|
EGFRm NSCLC with high levels of
MET overexpression and/or amplification
(SAVANNAH)
|
Clinically meaningful ORR
|
|
Calquence fixed
duration
|
Chronic lymphocytic leukaemia (AMPLIFY)
|
Primary endpoint met
|
|
|
Fasenra
|
Eosinophilic chronic rhinosinusitis with nasal polyps
(ORCHID)
|
Primary endpoint not met
|
|
|
Tezspire
|
Severe chronic rhinosinusitis with nasal polyps
(WAYPOINT)
|
Primary endpoint met
|
|
|
Koselugo
|
Adults with NF1-PN (KOMET)
|
Primary endpoint met
|
*US, EU and China regulatory submission denotes filing
acceptance
Upcoming pipeline catalysts
For recent trial starts and anticipated timings of key trial
readouts, please refer to the Clinical Trials Appendix, available
on www.astrazeneca.com/investor-relations.html.
Corporate and business development
In October 2024, AstraZeneca entered into an exclusive license
agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the
development of an early stage, novel small molecule Lipoprotein (a)
(Lp(a)) disruptor that has the potential to offer additional
benefits for patients with dyslipidaemia. This further strengthens
the company's cardiovascular portfolio to help address the major
risk factors driving chronic cardiovascular disease. Under the
terms of the agreement, AstraZeneca will receive access to CSPC's
pre-clinical candidate small molecule, YS2302018, an oral Lp(a)
disruptor, with the aim of developing this as a novel
lipid-lowering therapy with potential in a range of cardiovascular
disease indications alone or in combination, including with
AstraZeneca's oral small molecule PCSK9 inhibitor, AZD0780. CSPC
will receive an upfront payment of $100 million from AstraZeneca.
CSPC is also eligible to receive up to $1.92 billion for further
development and commercialisation milestones plus tiered
royalties.
In October 2024, AstraZeneca entered into an agreement to
out-license ALXN1840 (bis-choline tetrathiomolybdate), a drug
candidate for Wilson disease to Monopar Therapeutics Inc (Monopar).
Monopar will be responsible for all future global development and
commercialisation activities. AstraZeneca will have a 9.9%
beneficial ownership interest in Monopar upon issuance as well as
an upfront cash payment of $4.0 million. AstraZeneca is also
eligible to receive milestones and royalties.
Sustainability highlights
In September, AstraZeneca had a significant presence at Climate
Week NYC and the 79th Session of the UN General Assembly in New
York, with a delegation led by Pam Cheng, Executive Vice President
of Global Operations and IT and Chief Sustainability Officer and
the company's US leadership. A programme of more than 50
engagements with governments, media, NGOs and the private sector
focused on the interconnected issues of the climate crisis, health
equity and health system resilience and the Company's commitment to
contribute to more sustainable, resilient and equitable health
systems.
Conference call
A conference call and webcast for investors and analysts will begin
today, 12 November 2024, at 14:00 UK time. Details can be accessed
via astrazeneca.com.
Reporting calendar
The Company intends to publish its FY and Q4 2024 results on 6
February 2025.
Operating and financial review
All narrative on growth and results in this section is based on
actual exchange rates, and financial figures are in US$ millions
($m), unless stated otherwise. The performance shown in this
announcement covers the nine-month period to 30 September 2024
('the period' or '9M 2024') compared to the nine-month period to 30
September 2023 ('9M 2023'), or the three-month period to 30
September 2024 ('the quarter' or 'Q3 2024') compared to the
three-month period to 30 September 2023 ('Q3 2023'), unless stated
otherwise.
Core financial measures, EBITDA, Net debt, Product Sales Gross
Margin, Operating Margin and CER are non-GAAP financial measures
because they cannot be derived directly from the Group's Condensed
consolidated financial statements. Management believes that these
non-GAAP financial measures, when provided in combination with
Reported results, provide investors and analysts with helpful
supplementary information to understand better the financial
performance and position of the Group on a comparable basis from
period to period. These non-GAAP financial measures are not a
substitute for, or superior to, financial measures prepared in
accordance with GAAP.
Core financial measures are adjusted to exclude certain significant
items:
‒ Charges
and provisions related to our global restructuring programmes on
our capitalised manufacturing assets and IT
assets
‒ Amortisation
and impairment of intangible assets, including impairment reversals
but excluding any charges relating to IT assets
‒ Other
specified items, principally the imputed finance charges and fair
value movements relating to contingent consideration on business
combinations, imputed finance charges and remeasurement adjustments
on certain Other payables arising from intangible asset
acquisitions, legal settlements and remeasurement adjustments
relating to certain Other payables and debt items assumed from the
Alexion acquisition
‒ The
tax effects of the adjustments above are excluded from the Core Tax
charge
Details on the nature of Core financial measures are provided on
page 61 of the Annual Report and Form
20-F Information 2023.
Reference should be made to the Reconciliation of Reported to Core
financial measures table included in the financial performance
section in this announcement.
Product Sales Gross Margin is calculated by dividing the difference
between Product Sales and Cost of Sales by the Product
Sales. The calculation of
Reported and Core Product Sales Gross Margin excludes the impact of
Alliance Revenue and Collaboration Revenue and any associated
costs, thereby reflecting the underlying performance of Product
Sales.
EBITDA is defined as Reported Profit before tax after adding back
Net finance expense, results from Joint ventures and associates and
charges for Depreciation, amortisation and impairment. Reference
should be made to the Reconciliation of Reported Profit before tax
to EBITDA included in the financial performance section in this
announcement.
Operating margin is defined as Operating profit as a percentage of
Total Revenue.
Net debt is defined as Interest-bearing loans and borrowings and
Lease liabilities, net of Cash and cash equivalents, Other
investments, and Net derivative financial instruments. Reference
should be made to Note 3 'Net debt' included in the Notes to the
Interim financial statements in this announcement.
The Company strongly encourages investors and analysts not to rely
on any single financial measure, but to review AstraZeneca's
financial statements, including the Notes thereto, and other
available Company reports, carefully and in their
entirety.
Due to rounding, the sum of a number of dollar values and
percentages in this announcement may not agree to
totals.
Total Revenue
Table 4: Total
Revenue by therapy area and medicine[7]
|
|
|
9M 2024
|
Q3 2024
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
|
16,009
|
41
|
19
|
22
|
5,569
|
41
|
19
|
22
|
|
- Tagrisso
|
|
4,877
|
12
|
11
|
15
|
1,674
|
12
|
14
|
17
|
|
- Imfinzi
|
|
3,463
|
9
|
18
|
22
|
1,203
|
9
|
13
|
16
|
|
- Calquence
|
|
2,321
|
6
|
26
|
27
|
813
|
6
|
24
|
25
|
|
- Lynparza
|
|
2,228
|
6
|
8
|
10
|
778
|
6
|
11
|
13
|
|
- Enhertu
|
|
1,442
|
4
|
57
|
60
|
510
|
4
|
50
|
55
|
|
- Zoladex
|
|
845
|
2
|
17
|
24
|
278
|
2
|
12
|
18
|
|
- Imjudo
|
|
208
|
1
|
30
|
32
|
72
|
1
|
20
|
22
|
|
- Truqap
|
|
267
|
1
|
n/m
|
n/m
|
125
|
1
|
n/m
|
n/m
|
|
- Orpathys
|
|
36
|
-
|
5
|
8
|
11
|
-
|
(11)
|
(11)
|
|
-
Other Oncology
|
|
322
|
1
|
(18)
|
(12)
|
106
|
1
|
(10)
|
(5)
|
|
BioPharmaceuticals: CVRM
|
|
9,379
|
24
|
18
|
21
|
3,159
|
23
|
18
|
20
|
|
- Farxiga
|
|
5,779
|
15
|
32
|
34
|
1,943
|
14
|
25
|
27
|
|
- Brilinta
|
|
992
|
3
|
-
|
1
|
327
|
2
|
(1)
|
(1)
|
|
- Crestor
|
|
894
|
2
|
4
|
9
|
304
|
2
|
10
|
14
|
|
- Lokelma
|
|
392
|
1
|
31
|
34
|
143
|
1
|
40
|
42
|
|
- Seloken/Toprol-XL
|
|
466
|
1
|
(6)
|
(1)
|
151
|
1
|
(2)
|
1
|
|
-
roxadustat
|
|
261
|
1
|
23
|
26
|
95
|
1
|
26
|
25
|
|
- Andexxa
|
|
159
|
-
|
24
|
26
|
54
|
-
|
36
|
38
|
|
- Wainua
|
|
44
|
-
|
n/m
|
n/m
|
23
|
-
|
n/m
|
n/m
|
|
-
Other CVRM
|
|
392
|
1
|
(27)
|
(26)
|
120
|
1
|
(22)
|
(20)
|
|
BioPharmaceuticals: R&I
|
|
5,750
|
15
|
22
|
24
|
1,959
|
14
|
26
|
29
|
|
- Symbicort
|
|
2,195
|
6
|
19
|
22
|
705
|
5
|
27
|
31
|
|
- Fasenra
|
|
1,218
|
3
|
7
|
8
|
436
|
3
|
12
|
13
|
|
- Breztri
|
|
721
|
2
|
51
|
53
|
266
|
2
|
56
|
57
|
|
- Pulmicort
|
|
517
|
1
|
5
|
9
|
138
|
1
|
(6)
|
(4)
|
|
- Tezspire
|
|
471
|
1
|
>2x
|
>2x
|
191
|
1
|
>2x
|
>2x
|
|
- Saphnelo
|
|
327
|
1
|
71
|
72
|
124
|
1
|
63
|
64
|
|
- Airsupra
|
|
41
|
-
|
n/m
|
n/m
|
21
|
-
|
n/m
|
n/m
|
|
-
Other R&I
|
|
259
|
1
|
(28)
|
(27)
|
78
|
1
|
(32)
|
(32)
|
|
BioPharmaceuticals: V&I
|
|
811
|
2
|
(14)
|
(12)
|
460
|
3
|
48
|
49
|
|
- Beyfortus
|
|
319
|
1
|
>2x
|
>2x
|
238
|
2
|
73
|
72
|
|
- Synagis
|
|
346
|
1
|
(10)
|
(4)
|
93
|
1
|
(6)
|
3
|
|
-
COVID-19 mAbs
|
|
31
|
-
|
(90)
|
(90)
|
28
|
-
|
>10x
|
>10x
|
|
- FluMist
|
|
109
|
-
|
24
|
21
|
100
|
1
|
34
|
31
|
|
-
Other V&I
|
|
6
|
-
|
(79)
|
(80)
|
0
|
-
|
(63)
|
n/m
|
|
Rare Disease
|
|
6,391
|
16
|
10
|
14
|
2,148
|
16
|
9
|
11
|
|
- Ultomiris
|
|
2,835
|
7
|
32
|
35
|
1,031
|
8
|
33
|
35
|
|
- Soliris
|
|
2,045
|
5
|
(16)
|
(11)
|
606
|
4
|
(22)
|
(18)
|
|
- Strensiq
|
|
996
|
3
|
18
|
19
|
343
|
3
|
20
|
21
|
|
- Koselugo
|
|
366
|
1
|
49
|
55
|
119
|
1
|
37
|
39
|
|
- Kanuma
|
|
149
|
-
|
15
|
16
|
49
|
-
|
10
|
9
|
|
Other Medicines
|
|
843
|
2
|
(10)
|
(4)
|
270
|
2
|
(12)
|
(8)
|
|
- Nexium
|
|
685
|
2
|
(8)
|
(2)
|
216
|
2
|
(13)
|
(8)
|
|
-
Others
|
|
157
|
-
|
(17)
|
(15)
|
54
|
-
|
(7)
|
(7)
|
|
Total
|
|
39,182
|
100
|
16
|
19
|
13,565
|
100
|
18
|
21
|
Table 5: Alliance Revenue
|
|
|
9M 2024
|
Q3 2024
|
||||
|
|
|
|
% Change
|
|
% Change
|
||
|
|
|
$m
|
Actual
|
CER
|
$m
|
Actual
|
CER
|
|
Enhertu
|
|
1,045
|
41
|
42
|
361
|
36
|
38
|
|
Tezspire
|
|
303
|
69
|
69
|
123
|
65
|
65
|
|
Beyfortus
|
|
75
|
>4x
|
>4x
|
49
|
>2x
|
>2x
|
|
Other
Alliance Revenue
|
|
75
|
11
|
11
|
26
|
29
|
29
|
|
Total
|
|
1,498
|
49
|
50
|
559
|
48
|
50
|
Table 6: Collaboration Revenue
|
|
|
9M 2024
|
Q3 2024
|
||||
|
|
|
|
% Change
|
|
% Change
|
||
|
|
|
$m
|
Actual
|
CER
|
$m
|
Actual
|
CER
|
|
Farxiga: sales
milestones
|
|
52
|
87
|
87
|
3
|
12
|
14
|
|
Beyfortus: sales milestones
|
|
56
|
(21)
|
(23)
|
56
|
(21)
|
(23)
|
|
Total
|
|
108
|
(66)
|
(66)
|
59
|
(39)
|
(40)
|
Table 7: Total
Revenue by therapy area
|
|
|
9M 2024
|
Q3 2024
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
|
16,009
|
41
|
19
|
22
|
5,569
|
41
|
19
|
22
|
|
Biopharmaceuticals
|
|
15,940
|
41
|
17
|
20
|
5,578
|
41
|
23
|
25
|
|
CVRM
|
|
9,379
|
24
|
18
|
21
|
3,159
|
23
|
18
|
20
|
|
R&I
|
|
5,750
|
15
|
22
|
24
|
1,959
|
14
|
26
|
29
|
|
V&I
|
|
811
|
2
|
(14)
|
(12)
|
460
|
3
|
48
|
49
|
|
Rare Disease
|
|
6,391
|
16
|
10
|
14
|
2,148
|
16
|
9
|
11
|
|
Other Medicines
|
|
843
|
2
|
(10)
|
(4)
|
270
|
2
|
(12)
|
(8)
|
|
Total
|
|
39,182
|
100
|
16
|
19
|
13,565
|
100
|
18
|
21
|
Table 8: Total
Revenue by region
|
|
|
9M 2024
|
Q3 2024
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
US
|
|
16,703
|
43
|
20
|
20
|
6,008
|
44
|
23
|
23
|
|
Emerging Markets
|
|
10,541
|
27
|
14
|
23
|
3,423
|
25
|
15
|
23
|
|
China
|
|
5,049
|
13
|
12
|
15
|
1,671
|
12
|
15
|
15
|
|
Emerging Markets ex. China
|
|
5,492
|
14
|
16
|
30
|
1,752
|
13
|
16
|
31
|
|
Europe
|
|
8,240
|
21
|
22
|
22
|
2,875
|
21
|
22
|
22
|
|
Established ROW
|
|
3,698
|
9
|
(4)
|
4
|
1,260
|
9
|
(1)
|
4
|
|
Total
|
|
39,182
|
100
|
16
|
19
|
13,565
|
100
|
18
|
21
|
Oncology
Oncology Total Revenue of $16,009m in 9M 2024 increased by 19% (22%
at CER), representing 41% of overall Total Revenue (9M 2023:
40%).
Tagrisso
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
4,877
|
|
1,996
|
1,365
|
956
|
560
|
|
Actual change
|
|
11%
|
|
19%
|
8%
|
16%
|
(10%)
|
|
CER change
|
|
15%
|
|
19%
|
16%
|
16%
|
(2%)
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Strong global demand for Tagrisso in adjuvant (ADAURA) and 1st-line settings
(FLAURA, FLAURA-2)
|
|
US
|
|
∗ Continued demand growth in both the adjuvant and
metastatic settings, with some additional benefit coming from
improved affordability
|
|
Emerging Markets
|
|
∗ Encouraging demand growth, partly offset by NRDL
price reduction in prior year period
|
|
Europe
|
|
∗ Continued demand growth across adjuvant and
metastatic settings
|
|
Established RoW
|
|
∗ Continued demand growth across adjuvant and
metastatic settings with year-over-year comparison reflecting price
reduction in Japan in June 2023
|
Imfinzi
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
3,463
|
|
1,883
|
365
|
695
|
520
|
|
Actual change
|
|
18%
|
|
18%
|
37%
|
30%
|
(3%)
|
|
CER change
|
|
22%
|
|
18%
|
61%
|
29%
|
6%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Strong demand growth driven by BTC (TOPAZ-1), HCC
(HIMALAYA), and increased patient share in Stage IV NSCLC
(POSEIDON) and extensive-stage SCLC (CASPIAN)
|
|
US
|
|
∗ Continued demand growth driven primarily by HCC
and extensive-stage SCLC, having achieved peak market share as
established standard of care in BTC
|
|
Emerging Markets
|
|
∗ Strong demand growth driven across all approved
indications, in particular BTC
|
|
Europe
|
|
∗ Growth driven by share gains in extensive-stage
SCLC as well as new launches in HCC, BTC and
NSCLC
|
|
Established RoW
|
|
∗ Increased demand in GI
indications, with year-over-year comparison reflecting
the 25% and 11% mandatory price
reductions in Japan effective from 1 February 2024 and 1 August
2024 respectively
|
Calquence
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
2,321
|
|
1,617
|
116
|
489
|
99
|
|
Actual change
|
|
26%
|
|
21%
|
68%
|
38%
|
23%
|
|
CER change
|
|
27%
|
|
21%
|
90%
|
38%
|
27%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Sustained BTKi leadership in front-line CLL
(ELEVATE-TN)
|
|
US
|
|
∗ Growth driven by leading share of new patient
starts in front-line CLL, with some additional favourability coming
from improved affordability
|
|
Europe
|
|
∗ Strong growth momentum in front-line CLL,
maintaining share of 1L new patient starts in competitive
environment
|
Lynparza
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
2,228
|
|
954
|
475
|
612
|
187
|
|
Actual change
|
|
8%
|
|
6%
|
16%
|
13%
|
(13%)
|
|
CER change
|
|
10%
|
|
6%
|
25%
|
12%
|
(7%)
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Lynparza remains
the leading medicine in the PARP inhibitor class globally across
four tumour types (ovarian, breast, prostate, pancreatic), as
measured by total prescription volume
∗ No Collaboration Revenue
for Lynparza was recognised in either 9M 2024 or 9M
2023
|
|
US
|
|
∗ Continued leadership within competitive PARP
inhibitor class, with demand growth across all
indications
|
|
Emerging Markets
|
|
∗ Volume growth in China from increased share
following inclusion of HRD-positive ovarian cancer (PAOLA-1) on
NRDL with no price reduction
|
|
Europe
|
|
∗ Growth driven by increased market share and
additional launches in early breast cancer (OlympiA) and metastatic
prostate cancer (PROpel)
|
|
Established RoW
|
|
∗ PARP class leadership maintained with
year-over-year comparison reflecting 7.7% price reduction in Japan
in November 2023
|
Enhertu
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
1,442
|
|
642
|
353
|
400
|
47
|
|
Actual change
|
|
57%
|
|
24%
|
97%
|
95%
|
>2x
|
|
CER change
|
|
60%
|
|
24%
|
>2x
|
95%
|
>2x
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Established standard of care in HER2-positive
(DESTINY-Breast03) and HER2-low (DESTINY-Breast04) metastatic
breast cancer
∗ Encouraging early uptake, particularly in
gynaecological indications following tumour-agnostic approval in
April 2024 (DESTINY-PanTumor02, DESTINY-Lung01,
DESTINY-CRC02)
∗ Combined sales of Enhertu, recorded by Daiichi Sankyo and AstraZeneca,
amounted to $2,729m in 9M 2024 (9M 2023:
$1,844m)
|
|
US
|
|
∗ US in-market sales, recorded
by Daiichi Sankyo, amounted to $1,342m in 9M 2024 (9M 2023:
$1,087m)
|
|
Emerging Markets
|
|
∗ Increased demand growth following commercial
breast cancer launch in China in Q1 2024
|
|
Europe
|
|
∗ Continued demand growth due to increasing adoption
in HER2-positive and HER2-low metastatic breast
cancer
|
|
Established RoW
|
|
∗ AstraZeneca's Alliance Revenue includes a mid
single-digit percentage royalty on Daiichi Sankyo's sales in
Japan
|
Other Oncology medicines
|
|
9M 2024
|
Change
|
|
|||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
|
Zoladex
|
|
845
|
17%
|
24%
|
∗ Strong underlying growth in China and Emerging
Markets and moderate growth in Europe with reduced uptake in
Japan
|
|
|
Imjudo
|
|
208
|
30%
|
32%
|
∗ Continued growth across
markets
|
|
|
Truqap
|
|
267
|
n/m
|
n/m
|
∗ Strong demand growth with strong uptake in
biomarker altered subgroup of HR-positive HER2-negative metastatic
breast cancer (CAPItello-291)
|
|
|
Orpathys
|
|
36
|
5%
|
8%
|
∗ Demand in China for the treatment of patients with
NSCLC with MET exon 14 skipping alterations
|
|
|
Other Oncology
|
|
322
|
(18%)
|
(12%)
|
∗ Decline in Faslodex Total Revenue due to VBP implementation in
China in March 2024 and generic erosion in
Europe
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals
BioPharmaceuticals Total Revenue increased by 17% (20% at CER) in
9M 2024 to $15,940m, representing 41% of overall Total Revenue (9M
2023: 40%).
BioPharmaceuticals - CVRM
CVRM Total Revenue increased by 18% (21% at CER) to $9,379m in 9M
2024 and represented 24% of overall Total Revenue (9M 2023:
23%).
Farxiga
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
5,779
|
|
1,280
|
2,225
|
1,903
|
371
|
|
Actual change
|
|
32%
|
|
28%
|
34%
|
40%
|
(2%)
|
|
CER change
|
|
34%
|
|
28%
|
41%
|
39%
|
5%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Farxiga volume
continued to grow faster than the overall SGLT2 market in all major
regions, driven by continued demand in heart failure and
CKD
∗ SGLT2 class growth underpinned by updated
cardiorenal guidelines
|
|
US
|
|
∗ Growth driven by underlying demand in HFrEF and
CKD
∗ Launch of an authorised generic in the first
quarter of 2024
|
|
Emerging Markets
|
|
∗ Increased reimbursement supporting solid growth
despite entry of generic competition in some
markets
|
|
Europe
|
|
∗ Continued strong class growth
and market share gains
|
|
Established RoW
|
|
∗ Continued demand growth partially offset by
generic competition in Canada
∗ In Japan, AstraZeneca sells to collaborator Ono
Pharmaceutical Co., Ltd, which records in-market
sales
|
Other CVRM medicines
|
|
9M 2024
|
Change
|
|
|||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
|
Brilinta
|
|
992
|
-
|
1%
|
∗ Continued sales growth in Emerging Markets,
decline in Est. RoW driven by generic competition in
Canada
|
|
|
Crestor
|
|
894
|
4%
|
9%
|
∗ Continued sales growth in Emerging
Markets
|
|
|
Seloken
|
|
466
|
(6%)
|
(1%)
|
∗ Growth in ex-China EM markets offsetting declines
in other regions
|
|
|
Lokelma
|
|
392
|
31%
|
34%
|
∗ Strong growth in all major regions, particularly
in Europe and Emerging Markets. Continued launches in new
markets
|
|
|
Roxadustat
|
|
261
|
23%
|
26%
|
∗ Continued patient and volume
growth
|
|
|
Andexxa
|
|
159
|
24%
|
26%
|
∗ Demand growth
|
|
|
Wainua
|
|
44
|
n/m
|
n/m
|
∗ Encouraging launch uptake
following ATTRv-PN approval in the US in December 2023
|
|
|
Other CVRM
|
|
392
|
(27%)
|
(26%)
|
∗ Generic
competition
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals - R&I
Total Revenue of $5,750m from R&I medicines increased 22% (24%
at CER) and represented 15% of overall Total Revenue (9M 2023:
14%).
Fasenra
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
1,218
|
|
750
|
68
|
294
|
106
|
|
Actual change
|
|
7%
|
|
4%
|
43%
|
12%
|
(1%)
|
|
CER change
|
|
8%
|
|
4%
|
52%
|
11%
|
6%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Continued severe asthma market share leadership in
IL-5 class across major markets
|
|
US
|
|
∗ Sustained double-digit volume
growth
|
|
Emerging Markets
|
|
∗ Continued strong demand growth driven
by launch acceleration
across key markets
|
|
Europe
|
|
∗ Sustained leadership in
severe eosinophilic asthma
|
|
Established RoW
|
|
∗ In Japan, maintained class
leadership in a broadly stable market
|
Breztri
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
721
|
|
367
|
199
|
102
|
53
|
|
Actual change
|
|
51%
|
|
40%
|
62%
|
86%
|
42%
|
|
CER change
|
|
53%
|
|
40%
|
68%
|
85%
|
51%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Fastest growing
single-inhaler triple medicine within the expanding FDC
triple class
|
|
US
|
|
∗ Consistent share growth
within the expanding FDC triple class
|
|
Emerging Markets
|
|
∗ Maintained market share leadership in China with
strong FDC triple class penetration
∗ Further expansion with launches in additional
geographies
|
|
Europe
|
|
∗ Sustained growth across markets driven by new
launches
|
|
Established RoW
|
|
∗ Increased market share in
Japan
|
Tezspire
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
471
|
|
303
|
8
|
105
|
55
|
|
Actual change
|
|
>2x
|
|
70%
|
n/m
|
>3x
|
>2x
|
|
CER change
|
|
>2x
|
|
70%
|
n/m
|
>3x
|
>2x
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to
$843m in 9M 2024 (9M 2023: $438m)
|
|
US
|
|
∗ Continued growth in total prescriptions, with
majority of patients new-to-biologics
|
|
Europe
|
|
∗ Achieved and maintained
new-to-brand leadership across multiple markets, new launches
continue to progress
|
|
Established RoW
|
|
∗ Sustained market share growth
in Japan and other major geographies, with continued
launches
|
Symbicort
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
2,195
|
|
887
|
653
|
415
|
240
|
|
Actual change
|
|
19%
|
|
51%
|
9%
|
2%
|
(2%)
|
|
CER change
|
|
22%
|
|
51%
|
19%
|
1%
|
-
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Symbicort remained the global
market leader within a stable ICS/LABA class
|
|
US
|
|
∗ Continued strong demand
for the authorised generic, limitation of patient out-of-pocket
expenses and favourable channel mix
|
|
Emerging Markets
|
|
∗ Sustained demand growth across
markets
|
|
Europe
|
|
∗ Continued growth in some
markets within mild asthma partially offset generic erosion and a
slowing overall market
|
|
Established RoW
|
|
∗ Continued generic erosion in
Japan
|
Other R&I medicines
|
|
9M 2024
|
Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
||
|
Saphnelo
|
|
327
|
71%
|
72%
|
∗ Demand acceleration in the US,
and additional growth driven by ongoing launches in Europe and
Established RoW
|
||
|
Airsupra
|
|
41
|
n/m
|
n/m
|
∗ Strong US launch momentum and
volume uptake. Revenue in the period reflects introductory
discounts as early access continues to build
|
||
|
Pulmicort
|
|
517
|
5%
|
9%
|
∗ >80% of revenues from
Emerging Markets
|
||
|
Other R&I
|
|
259
|
(28%)
|
(27%)
|
∗ Continued generic
competition
|
||
|
|
|
|
|
|
|
|
|
BioPharmaceuticals - V&I
Total Revenue from V&I medicines reduced by 14% (12% at CER) to
$811m (9M 2023: $944m) and represented 2% of overall Total Revenue
(9M 2023: 3%).
V&I medicines
|
|
9M 2024
|
Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
||
|
Beyfortus
|
|
319
|
>2x
|
>2x
|
∗ Growth driven increasing demand and expanded
production capacity
∗ Product Sales recognises AstraZeneca's sales of
manufactured Beyfortus product to Sanofi
∗ Alliance Revenue recognises AstraZeneca's 50%
share of gross profits on sales of Beyfortus in major markets outside the US, and 25% of
brand revenues in rest of world markets
∗ AstraZeneca has no participation in US profits or
losses
|
||
|
Synagis
|
|
346
|
(10%)
|
(4%)
|
∗ As anticipated, Synagis demand decreased following rapid adoption
of Beyfortus
|
||
|
COVID-19 mAbs
|
|
31
|
(90%)
|
(90%)
|
∗ Decline in Evusheld sales and Collaboration
Revenue (Total Revenue 9M 2023: $306m)
|
||
|
FluMist
|
|
109
|
24%
|
21%
|
∗ Demand growth across key
markets in particular Europe and benefit from earlier start in flu
season in Q3 2024 compared to prior year
|
||
|
Other V&I
|
|
6
|
(79%)
|
(80%)
|
∗ Decline in Vaxzevria sales (9M 2023: $28m)
|
||
|
|
|
|
|
|
|
|
|
Rare Disease
Total Revenue from Rare Disease medicines increased by 10% (14% at
CER) in 9M 2024 to $6,391m, representing 16% of overall Total
Revenue (9M 2023: 17%).
Ultomiris
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
2,835
|
|
1,629
|
92
|
649
|
465
|
|
Actual change
|
|
32%
|
|
29%
|
97%
|
31%
|
37%
|
|
CER change
|
|
35%
|
|
29%
|
>2x
|
30%
|
50%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Growth due to increased use in neurology,
geographic expansion, further patient demand and conversion
from Soliris
∗ Ultomiris Total
Revenue includes sales of Voydeya, which is approved as an add-on treatment
to Ultomiris and Soliris for the 10-20% of PNH patients who
experience clinically significant EVH
|
|
US
|
|
∗ Strong growth in patient demand in gMG
(CHAMPION-MG) and NMOSD (CHAMPION-NMOSD), both new to branded
medicines, as well as continued conversion
from Soliris
|
|
Emerging Markets
|
|
∗ Expansion into new markets and growth in patient
demand
|
|
Europe
|
|
∗ Strong demand growth following recent launches,
particularly from neurology indications, accelerated conversion
from Soliris, partially offset by price reductions to secure
reimbursement for new indications
|
|
Established RoW
|
|
∗ Continued conversion from Soliris and strong demand following new
launches
|
Soliris
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
2,045
|
|
1,170
|
365
|
346
|
164
|
|
Actual change
|
|
(16%)
|
|
(11%)
|
8%
|
(35%)
|
(34%)
|
|
CER change
|
|
(11%)
|
|
(11%)
|
39%
|
(35%)
|
(31%)
|
|
Region
|
|
Drivers and commentary
|
|
US
|
|
∗ Decline driven by successful conversion
of Soliris patients to Ultomiris
|
|
Emerging Markets
|
|
∗ Growth driven by patient
demand
|
|
Europe
|
|
∗ Decline driven by biosimilar erosion in PNH and
aHUS and successful conversion from Soliris to Ultomiris
|
|
Established RoW
|
|
∗ Decline driven by successful conversion
from Soliris to Ultomiris
|
Strensiq
|
9M 2024, $m
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Total Revenue
|
|
996
|
|
815
|
39
|
73
|
69
|
|
Actual change
|
|
18%
|
|
18%
|
34%
|
15%
|
8%
|
|
CER change
|
|
19%
|
|
18%
|
48%
|
14%
|
18%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Growth driven by strong patient
demand
|
Other Rare Disease medicines
|
|
9M 2024
|
Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
||
|
Koselugo
|
|
366
|
49%
|
55%
|
∗ Driven by patient demand and expansion in new
markets
|
||
|
Kanuma
|
|
149
|
15%
|
16%
|
∗ Continued global demand
|
||
|
|
|
|
|
|
|
|
|
Other medicines (outside the main therapy areas)
|
|
9M 2024
|
Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
||
|
Nexium
|
|
685
|
(8%)
|
(2%)
|
∗ Stable in Emerging Markets, which now accounts for
two-thirds of Nexium revenue, offset by generic erosion in other
markets
|
||
|
Others
|
|
157
|
(17%)
|
(15%)
|
∗ Continued impact of generic
competition
|
||
|
|
|
|
|
|
|
|
|
Financial performance
Table 9:
Reported Profit and Loss
|
|
|
9M 2024
|
9M 2023
|
% Change
|
Q3 2024
|
Q3 2023
|
% Change
|
||
|
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
|
39,182
|
33,787
|
16
|
19
|
13,565
|
11,492
|
18
|
21
|
|
- Product Sales
|
|
37,576
|
32,466
|
16
|
19
|
12,947
|
11,018
|
18
|
20
|
|
- Alliance Revenue
|
|
1,498
|
1,004
|
49
|
50
|
559
|
377
|
48
|
50
|
|
- Collaboration Revenue
|
|
108
|
317
|
(66)
|
(66)
|
59
|
97
|
(39)
|
(40)
|
|
Cost of sales
|
|
(7,482)
|
(5,960)
|
26
|
28
|
(3,081)
|
(2,095)
|
47
|
48
|
|
Gross profit
|
|
31,700
|
27,827
|
14
|
17
|
10,484
|
9,397
|
12
|
15
|
|
Distribution expense
|
|
(412)
|
(394)
|
4
|
7
|
(145)
|
(129)
|
12
|
15
|
|
R&D expense
|
|
(8,906)
|
(7,862)
|
13
|
14
|
(3,115)
|
(2,584)
|
21
|
21
|
|
SG&A expense
|
|
(14,567)
|
(13,845)
|
5
|
7
|
(5,143)
|
(4,800)
|
7
|
8
|
|
Other operating income & expense
|
|
152
|
1,233
|
(88)
|
(88)
|
25
|
70
|
(65)
|
(61)
|
|
Operating profit
|
|
7,967
|
6,959
|
14
|
23
|
2,106
|
1,954
|
8
|
18
|
|
Net finance expense
|
|
(919)
|
(945)
|
(3)
|
(7)
|
(274)
|
(291)
|
(6)
|
(15)
|
|
Joint ventures and associates
|
|
(23)
|
(12)
|
n/m
|
97
|
(4)
|
(11)
|
(53)
|
(54)
|
|
Profit before tax
|
|
7,025
|
6,002
|
17
|
28
|
1,828
|
1,652
|
11
|
24
|
|
Taxation
|
|
(1,484)
|
(1,000)
|
48
|
62
|
(395)
|
(274)
|
44
|
62
|
|
Tax rate
|
|
21%
|
17%
|
|
|
22%
|
17%
|
|
|
|
Profit after tax
|
|
5,541
|
5,002
|
11
|
21
|
1,433
|
1,378
|
4
|
17
|
|
Earnings per share
|
|
$3.57
|
$3.22
|
11
|
21
|
$0.92
|
$0.89
|
4
|
17
|
Table 10:
Reconciliation of Reported Profit before tax to
EBITDA
|
|
|
9M 2024
|
9M 2023
|
% Change
|
Q3 2024
|
Q3 2023
|
% Change
|
||
|
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit before tax
|
|
7,025
|
6,002
|
17
|
28
|
1,828
|
1,652
|
11
|
24
|
|
Net finance expense
|
|
919
|
945
|
(3)
|
(7)
|
274
|
291
|
(6)
|
(15)
|
|
Joint ventures and associates
|
|
23
|
12
|
n/m
|
97
|
4
|
11
|
(53)
|
(54)
|
|
Depreciation, amortisation and impairment
|
|
4,351
|
4,060
|
7
|
7
|
1,817
|
1,282
|
41
|
41
|
|
EBITDA
|
|
12,318
|
11,019
|
12
|
17
|
3,923
|
3,236
|
21
|
27
|
|
9M 2024
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Other
|
Core
|
Core
% Change
|
||||
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|||
|
Gross profit
|
|
31,700
|
655
|
24
|
4
|
32,383
|
15
|
19
|
|||
|
Product Sales Gross Margin
|
|
80%
|
|
|
|
82%
|
-
|
-
|
|||
|
Distribution expense
|
|
(412)
|
-
|
-
|
-
|
(412)
|
4
|
7
|
|||
|
R&D expense
|
|
(8,906)
|
221
|
38
|
9
|
(8,638)
|
17
|
18
|
|||
|
% of Total Revenue
|
|
23%
|
|
|
|
22%
|
-
|
-
|
|||
|
SG&A expense
|
|
(14,567)
|
180
|
3,343
|
291
|
(10,753)
|
11
|
13
|
|||
|
% of Total Revenue
|
|
37%
|
|
|
|
27%
|
+1pp
|
+1pp
|
|||
|
Total operating expense
|
|
(23,885)
|
401
|
3,381
|
300
|
(19,803)
|
13
|
15
|
|||
|
Other operating income & expense
|
|
152
|
(2)
|
-
|
(1)
|
149
|
(87)
|
(87)
|
|||
|
Operating profit
|
|
7,967
|
1,054
|
3,405
|
303
|
12,729
|
8
|
13
|
|||
|
Operating Margin
|
|
20%
|
|
|
|
32%
|
-2pp
|
-2pp
|
|||
|
Net finance expense
|
|
(919)
|
-
|
-
|
60
|
(859)
|
18
|
13
|
|||
|
Taxation
|
|
(1,484)
|
(189)
|
(621)
|
(67)
|
(2,361)
|
15
|
22
|
|||
|
EPS
|
|
$3.57
|
$0.56
|
$1.80
|
$0.19
|
$6.12
|
5
|
11
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
Table 12:
Reconciliation of Reported to Core financial measures: Q3
20247
|
Q3 2024
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Other
|
Core
|
Core
% Change
|
||||
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|||
|
Gross profit
|
|
10,484
|
619
|
8
|
1
|
11,112
|
18
|
21
|
|||
|
Product Sales Gross Margin
|
|
76%
|
|
|
|
81%
|
-
|
-
|
|||
|
Distribution expense
|
|
(145)
|
-
|
-
|
-
|
(145)
|
12
|
15
|
|||
|
R&D expense
|
|
(3,115)
|
44
|
1
|
2
|
(3,068)
|
23
|
24
|
|||
|
% of Total Revenue
|
|
23%
|
|
|
|
23%
|
-1pp
|
-1pp
|
|||
|
SG&A expense
|
|
(5,143)
|
42
|
1,460
|
36
|
(3,605)
|
8
|
9
|
|||
|
% of Total Revenue
|
|
38%
|
|
|
|
27%
|
+3pp
|
+3pp
|
|||
|
Total operating expense
|
|
(8,403)
|
86
|
1,461
|
38
|
(6,818)
|
14
|
16
|
|||
|
Other operating income & expense
|
|
25
|
-
|
-
|
(1)
|
24
|
(65)
|
(61)
|
|||
|
Operating profit
|
|
2,106
|
705
|
1,469
|
38
|
4,318
|
22
|
27
|
|||
|
Operating Margin
|
|
16%
|
|
|
|
32%
|
+1pp
|
+2pp
|
|||
|
Net finance expense
|
|
(274)
|
-
|
-
|
(55)
|
(329)
|
46
|
35
|
|||
|
Taxation
|
|
(395)
|
(109)
|
(254)
|
5
|
(753)
|
21
|
28
|
|||
|
EPS
|
|
$0.92
|
$0.38
|
$0.78
|
-
|
$2.08
|
20
|
27
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit and Loss drivers
Gross profit
‒ The
calculation of Reported and Core Product Sales Gross Margin
excludes the impact of Alliance Revenue and Collaboration
Revenue
‒ The
change in Product Sales Gross Margin (Reported and Core) in 9M 2024
was impacted by:
‒ Positive
effects from product mix. The increased contribution from Rare
Disease and Oncology medicines had a positive impact on the Product
Sales Gross Margin
‒ Dilutive
effects from product mix. The rising contribution of Product Sales
with profit sharing arrangements (Lynparza,
Enhertu, Tezspire,
Koselugo) has a negative
impact on Product Sales Gross Margin because AstraZeneca records
Product Sales in certain markets and pays away a share of the gross
profits to its collaboration partners. The growth
in Beyfortus also has a dilutive impact on Product Sales
Gross Margin, as AstraZeneca is responsible for manufacturing, and
Sanofi is responsible for distribution. AstraZeneca records its
sales to Sanofi as Product Sales, and those sales generate a lower
Product Sales Gross Margin than the Company
average
‒ Dilutive
effects from geographic mix. In Emerging Markets, the Product Sales
Gross Margin tends to be below the Company
average
‒ The
reported Product Sales Gross Margin included inventory and related
contract provisions of $638m recorded in the third quarter related
to Andexxa, which was part of the PAAGR restructuring
program (see Note 2 in the Notes to the interim financial
statements section)
‒ Variations
in Product Sales Gross Margin performance between periods can
continue to be expected due to product seasonality, foreign
exchange fluctuations, and other effects
R&D expense
‒ The
change in R&D expense (Reported and Core) in the period was
impacted by:
‒ Positive
data read-outs for several high priority medicines that have
ungated late-stage trials
‒ Investment
in platforms, new technology and capabilities to enhance R&D
capabilities
‒ Addition
of R&D projects following completion of previously announced
business development activity including Icosavax, Gracell, Fusion
and Amolyt
‒ The
change in Reported R&D expense was also impacted by intangible
asset impairments in the prior period
SG&A expense
‒ The
change in SG&A expense (Reported and Core) in the period was
driven primarily by market development activities for launches and
to support continued growth in existing brands
‒ The
Reported SG&A expense included impairment charges in the third
quarter of $504m recorded against the Andexxa intangible asset
Other operating income and expense
‒ In
the prior year period, Other operating income and expense included
a $241m gain on the disposal of the US rights
to Pulmicort
Flexhaler and a $712m gain
relating to contractual arrangements for Beyfortus
Net finance expense
‒ Core
Net finance expense increased 18% (13% increase at CER) due to the
increased level of debt and new debt issued at higher interest
rates
Taxation
‒ The
effective Reported Tax rate for the nine months to 30 September
2024 was 21% (9M 2023: 17%) and the effective Core Tax rate was 20%
(9M 2023: 19%)
‒ The
cash tax paid for the nine months to 30 September 2024 was $1,978m
(9M 2023: $1,710m), representing 28% of Reported Profit before tax
(9M 2023: 26%)
Table 13: Cash
Flow summary
|
|
|
9M 2024
|
9M 2023
|
Change
|
|
|
|
$m
|
$m
|
$m
|
|
Reported Operating profit
|
|
7,967
|
6,959
|
1,008
|
|
Depreciation, amortisation and impairment
|
|
4,351
|
4,060
|
291
|
|
Movement in working capital and short-term provisions
|
|
(543)
|
150
|
(693)
|
|
Gains on disposal of intangible assets
|
|
(34)
|
(247)
|
213
|
|
Fair value movements on contingent consideration arising
from
business combinations
|
|
251
|
202
|
49
|
|
Non-cash and other movements
|
|
15
|
(623)
|
638
|
|
Interest paid
|
|
(1,075)
|
(826)
|
(249)
|
|
Taxation paid
|
|
(1,978)
|
(1,710)
|
(268)
|
|
Net cash inflow from operating activities
|
|
8,954
|
7,965
|
989
|
|
Net cash inflow before financing activities
|
|
2,155
|
4,978
|
(2,823)
|
|
Net cash inflow/(outflow) from financing activities
|
|
(3,325)
|
(6,276)
|
2,951
|
The change in Net cash inflow before financing activities of
$2,823m is primarily driven by Acquisitions of subsidiaries, net of
cash acquired of $2,771m, and relates to the acquisition of Gracell
Biotechnologies, Inc. for $774m and acquisition of Fusion
Pharmaceuticals Inc., for $1,997m as compared to the acquisition of
Neogene Therapeutics, Inc. for $189m in 9M 2023.
The decrease in Net cash outflow from financing activities of
$2,951m is primarily driven by increased issuance of long-term
loans of $6,492m in the period compared to $3,816m issued in the
comparative period.
Capital expenditure
Capital expenditure amounted to $1,216m in 9M 2024 (9M 2023:
$836m). The increase of capital expenditure in 2024 is driven by
investment in several major manufacturing projects and continued
investment in technology upgrades.
Table 14: Net
debt summary
|
|
At 30
Sep 2024
|
At 31
Dec 2023
|
At 30
Sep 2023
|
|
|
$m
|
$m
|
$m
|
|
Cash and cash equivalents
|
4,797
|
5,840
|
4,871
|
|
Other investments
|
133
|
122
|
244
|
|
Cash and investments
|
4,930
|
5,962
|
5,115
|
|
Overdrafts and short-term borrowings
|
(769)
|
(515)
|
(515)
|
|
Commercial paper
|
(472)
|
-
|
-
|
|
Lease liabilities
|
(1,422)
|
(1,128)
|
(979)
|
|
Current instalments of loans
|
(12)
|
(4,614)
|
(4,857)
|
|
Non-current instalments of loans
|
(28,887)
|
(22,365)
|
(22,225)
|
|
Interest-bearing loans and borrowings (Gross debt)
|
(31,562)
|
(28,622)
|
(28,576)
|
|
Net derivatives
|
284
|
150
|
90
|
|
Net debt
|
(26,348)
|
(22,510)
|
(23,371)
|
Net debt increased by $3,838m in the nine months to 30 September
2024 to $26,348m. Details of the committed undrawn bank facilities
are disclosed within the going concern section of Note 1. Details
of the Company's solicited credit ratings and further details on
Net debt are disclosed in Note 3.
Capital allocation
The Company's capital allocation priorities include: investing in
the business and pipeline; maintaining a strong, investment-grade
credit rating; potential value-enhancing business development
opportunities; and supporting the progressive dividend policy. As
announced at the Annual General Meeting on 11 April 2024, the total
dividend for FY 2024 will increase by $0.20 per share to $3.10 per
share.
In approving the declaration of dividends, the Board considers both
the liquidity of the company and the level of reserves legally
available for distribution. Dividends are paid to shareholders from
AstraZeneca PLC, a Group holding company with no direct operations.
The ability of AstraZeneca PLC to make shareholder distributions is
dependent on the creation of profits for distribution and the
receipt of funds from subsidiary companies. The consolidated Group
reserves set out in the Condensed consolidated statement of
financial position do not reflect the profit available for
distribution to the shareholders of AstraZeneca PLC.
Summarised financial information for guarantee of securities of
subsidiaries
AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of
1.2% Notes due 2026, 4.8% Notes due 2027, 4.875% Notes due 2028,
1.75% Notes due 2028, 4.85% Notes due 2029, 4.9% Notes due 2030,
4.9% Notes due 2031, 2.25% Notes due 2031, 4.875% Notes due 2033,
5% Notes due 2034, 3.121% EUR Notes due 2030 and 3.278% EUR Notes
due 2033 (the "AstraZeneca Finance Notes"). Each series of
AstraZeneca Finance Notes has been fully and unconditionally
guaranteed by AstraZeneca PLC. AstraZeneca Finance is 100% owned by
AstraZeneca PLC and each of the guarantees issued by AstraZeneca
PLC is full and unconditional and joint and several.
The AstraZeneca Finance Notes are senior unsecured obligations of
AstraZeneca Finance and rank equally with all of AstraZeneca
Finance's existing and future senior unsecured and unsubordinated
indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca
Finance Notes is the senior unsecured obligation of AstraZeneca PLC
and ranks equally with all of AstraZeneca PLC's existing and future
senior unsecured and unsubordinated indebtedness. Each guarantee by
AstraZeneca PLC is effectively subordinated to any secured
indebtedness of AstraZeneca PLC to the extent of the value of the
assets securing such indebtedness. The AstraZeneca Finance Notes
are structurally subordinated to indebtedness and other liabilities
of the subsidiaries of AstraZeneca PLC, none of which guarantee the
AstraZeneca Finance Notes.
AstraZeneca PLC manages substantially all of its operations through
divisions, branches and/or investments in subsidiaries and
affiliates. Accordingly, the ability of AstraZeneca PLC to service
its debt and guarantee obligations is also dependent upon the
earnings of its subsidiaries, affiliates, branches and divisions,
whether by dividends, distributions, loans or
otherwise.
Please refer to the Consolidated financial statements of
AstraZeneca PLC in our Annual Report on Form 20-F as filed with the
SEC and information contained herein for further financial
information regarding AstraZeneca PLC and its consolidated
subsidiaries. For further details, terms and conditions of the
AstraZeneca Finance Notes please refer to AstraZeneca PLC's reports
on Form 6-K furnished to the SEC on 30 July 2024, 22 February 2024,
3 March 2023 and 28 May 2021.
Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the
Securities Act of 1933, as amended (the "Securities Act"), we
present below the summary financial information for AstraZeneca
PLC, as Guarantor, excluding its consolidated subsidiaries, and
AstraZeneca Finance, as the issuer, excluding its consolidated
subsidiaries. The following summary financial information of
AstraZeneca PLC and AstraZeneca Finance is presented on a combined
basis and transactions between the combining entities have been
eliminated. Financial information for non-guarantor entities has
been excluded. Intercompany balances and transactions between the
obligor group and the non-obligor subsidiaries are presented on
separate lines.
Table 15:
Obligor group summarised Statement of comprehensive
income
|
|
|
9M 2024
|
9M 2023
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
-
|
-
|
|
Gross profit
|
|
-
|
-
|
|
Operating loss
|
|
-
|
(2)
|
|
Loss for the period
|
|
(894)
|
(695)
|
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
1,342
|
9,758
|
Table 16:
Obligor group summarised Statement of financial
position
|
|
|
At 30 Sep 2024
|
At 30 Sep 2023
|
|
|
|
$m
|
$m
|
|
Current assets
|
|
10
|
6
|
|
Non-current assets
|
|
84
|
-
|
|
Current liabilities
|
|
(801)
|
(4,760)
|
|
Non-current liabilities
|
|
(28,906)
|
(22,077)
|
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
16,705
|
12,921
|
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
-
|
(295)
|
Foreign exchange
The Company's transactional currency exposures on working capital
balances, which typically extend for up to three months, are hedged
where practicable using forward foreign exchange contracts against
the individual companies' reporting currency. Foreign exchange
gains and losses on forward contracts transacted for transactional
hedging are taken to profit or to Other comprehensive income if the
contract is in a designated cashflow hedge. In addition, the
Company's external dividend payments, paid principally in pound
sterling and Swedish krona, are fully hedged from announcement to
payment date.
Table 17:
Currency sensitivities
The Company provides the following information on
currency-sensitivity:
|
|
|
|
Average
rates vs. USD
|
|
Annual impact ($m) of 5% strengthening (FY 2024 average rate vs. FY
2023 average) [9]
|
|||||||||||
|
Currency
|
Primary Relevance
|
|
FY 2023[10]
|
YTD 2024[11]
|
Change
(%)
|
Sep 2024[12]
|
Change
(%)
|
|
Total Revenue
|
Core Operating Profit
|
||||||
|
EUR
|
Total Revenue
|
|
0.92
|
0.92
|
0
|
0.90
|
3
|
|
397
|
179
|
||||||
|
CNY
|
Total Revenue
|
|
7.09
|
7.21
|
(2)
|
7.08
|
0
|
|
322
|
182
|
||||||
|
JPY
|
Total Revenue
|
|
140.60
|
151.23
|
(7)
|
143.04
|
(2)
|
|
177
|
119
|
||||||
|
Other[13]
|
|
|
|
|
|
|
|
|
453
|
227
|
||||||
|
GBP
|
Operating expense
|
|
0.80
|
0.78
|
3
|
0.76
|
6
|
|
60
|
(126)
|
||||||
|
SEK
|
Operating expense
|
|
10.61
|
10.50
|
1
|
10.23
|
4
|
|
9
|
(63)
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sustainability
In September, AstraZeneca had a significant presence at Climate
Week NYC and the 79th Session of the UN General Assembly in New
York, with a delegation led by Pam Cheng, Executive Vice President
of Global Operations and IT and Chief Sustainability Officer and
the company's US leadership. A programme of more than 50
engagements with governments, media, NGOs and the private sector
focused on the interconnected issues of the climate crisis, health
equity and health system resilience and the Company's commitment to
contribute to more sustainable, resilient and equitable health
systems.
Related communications included an opinion piece published by the
World Economic Forum (WEF) on how pharmaceutical companies are
investing in nature to improve human and planetary health and an
article in Foreign Policy on building sustainable health systems to
manage the burden of non-communicable diseases.
Access to healthcare
‒ By
end of August 2024, the Company's flagship Healthy Heart Africa
programme had conducted more than 61 million blood pressure
screenings, identifying over 12.1 million people with elevated
blood pressure and diagnosing over 4.87 million with high blood
pressure
‒ In
October, the Company convened the inaugural meeting of
its Global Health Equity Advisory Board (HEAB), a group of 15
external stakeholders with representation from 11 countries and
across disease areas, to advise on the Company's approach to help
improve equitable health outcomes globally
‒ AstraZeneca
Chair Michel Demaré and Executive Vice President, Vaccines and
Immune Therapies, Iskra Reic shared perspectives on health systems
resilience in Health: A Political Choice - Building Resilience and
Trust, a publication launched during the World Health Summit in
collaboration with the World Health
Organization
‒ During
the quarter, the Partnership for Health System Sustainability and
Resilience (PHSSR) initiative convened an Expert Advisory Group on
the role of EU institutions in supporting sustainable healthcare
financing of Member States. The PHSSR was also active in a session
at the European Health Forum Gastein in collaboration with
AstraZeneca, on the importance of decarbonising care pathways for
the health of people and the planet. The session emphasised the
need for early, targeted and patient-centred interventions within
integrated EU and national public policy
strategies
‒ In
September, through the Young Health Programme (YHP), 24 young
health leaders from around the world received a Fellowship to
attend the One Young World Summit in Montréal, Canada to
support their focus on building a healthier and more equitable
future. Additionally, in August, the YHP awarded scholarships to
seven young global leaders who are tackling the health impacts of
the climate crisis to join a Climate Entrepreneurship Academy in
New York. During the quarter, YHP won Corporate Social
Responsibility Programme of the Year at the Pharma Industry UK
Awards
Environmental protection
‒ The
Company reached a key sustainability milestone in its Ambition Zero
Carbon decarbonisation strategy, with over 50% of its global
vehicle fleet now fully electric, including in Europe, Japan and
the US. AstraZeneca currently has over 10,000 battery electric
vehicles (BEVs), with fully electric fleets in the Netherlands,
Greece and Georgia
‒ AstraZeneca's
manufacturing site in Södertälje, Sweden - the Company's
largest manufacturing site globally - has reduced its Scope 1 and 2
greenhouse (GHG) gas emissions by 98% since 2015, making it the
Company's sixth site to have achieved this goal ahead of schedule.
With this milestone, all locations in Sweden, including the
strategic R&D Centre in Gothenburg, have now achieved their
Scope 1 and 2 Ambition Zero Carbon Targets
‒ Through
the Sustainable Markets Initiative Health Systems Task Force,
chaired by CEO Pascal Soriot, the Company contributed to the launch
of the European Network on Climate and Health Education which took
place at the World Health Summit in Berlin. The network brings
together 25 leading universities from across Europe which are
committed to training 10,000 medical students with skills to
address the health impacts of climate change and deliver
sustainable healthcare
‒ The
Company received the Net Zero: Operations Transformation award at
the 2024 Reuters Sustainability Awards in October, recognising its
commitment to drive deep decarbonisation across its operations and
fleet through the Ambition Zero Carbon strategy. The WEF also
recognised two of the Company's advanced manufacturing sites in
Wuxi (China) and Södertälje (Sweden) as Fourth Industrial
Revolution (4IR) Lighthouses, part of its Global Lighthouse Network
which spotlights organisations harnessing advanced technologies
such as digital and AI to drive next-generation operational
excellence, environmental sustainability and workforce
development
‒ In
August, the Company was recognised with awards by My Green Lab and
the International Institute for Sustainable Laboratories - the 2024
Freezer Challenge Winning Streak Award for Biotech &
Pharmaceuticals, for being at the top of the sector and surpassing
2023 energy savings, and the Top Small Lab Award - Pharmaceutical
and Biotech Sector - awarded to AZ Gothenburg Regional HBS
Centre
‒ The
Company completed studies to support the first regulatory filings
for the transition of Breztri/Trixeo
Aerosphere to an
innovative, next-generation propellant with 99.9% lower Global
Warming Potential than propellants used in currently available
inhaled medicines. Reducing the carbon impact of
pressurised-metered dose inhalers is a key product-related element
of AstraZeneca's Ambition Zero Carbon strategy, alongside the
Company's commitment to improving patient
outcomes
Ethics and transparency
‒ In
September, AstraZeneca was included in the TIME World's Best
Companies 2024, ranking first among pharmaceutical companies for
sustainability transparency and in the top 70 out of 1,000
overall
‒ In
Mexico, AstraZeneca was third in the Great Place to Work (GPTW)
ranking and the Company's Guadalajara Global Innovation &
Technology Centre was number one in the GPTW Western Region for
companies with >500-5,000 employees for the fourth year in a
row
‒ AstraZeneca
and 33 other partner organisations announced the launch of the
VICT3R project, a public-private partnership that aims to reduce
the number of animals used in experimental studies through Virtual
Control Groups (VCGs) created using cutting edge statistical and
artificial intelligence (AI) techniques. The project aims to
transform drug and chemical safety evaluation while promoting
ethical research practices and environmental
sustainability
Research and development
This section covers R&D events and milestones that have
occurred since the prior results announcement on 25 July 2024,
up to and including events on 11 November 2024.
A comprehensive view of AstraZeneca's pipeline of medicines in
human trials can be found in the latest Clinical Trials Appendix,
available on www.astrazeneca.com/investor-relations.
The Clinical Trials Appendix includes tables with details of the
ongoing clinical trials for AstraZeneca medicines and new molecular
entities in the pipeline.
Oncology
AstraZeneca presented new data across its diverse portfolio of
cancer medicines at two major medical congresses since the prior
results announcement: the IASLC 2024 World Conference on Lung
Cancer (WCLC) hosted by the International Association for the Study
of Lung Cancer and the 2024 European Society for Medical Oncology
(ESMO) Congress. Across the two meetings, more than 130 abstracts
were presented featuring 17 approved and potential new medicines
including five Presidential Symposia and 41 oral
presentations.
Tagrisso
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
For the treatment of adult patients with unresectable, Stage
III EGFRm NSCLC whose disease has not progressed during or
following concurrent or sequential platinum-based chemoradiation
therapy. (LAURA, September 2024)
|
|
Phase II registrational trial readout
|
SAVANNAH
|
|
Tagrisso plus Orpathys demonstrated a high, clinically meaningful
and durable objective response rate for patients
with EGFRm NSCLC with high levels of mesenchymal epithelial
transition factor (MET) overexpression and/or amplification,
defined as IHC90+ and/or FISH10+, whose disease progressed on
treatment with Tagrisso. (October 2024)
|
Imfinzi and Imjudo
|
Event
|
|
|
Commentary
|
|
Approval
|
Europe
|
|
Imfinzi plus chemotherapy
followed by Imfinzi alone has been approved for patients with
mismatch repair deficient disease. (DUO-E, August
2024)
|
|
Approval
|
Europe
|
|
Imfinzi plus chemotherapy
as 1st-line treatment followed by Lynparza and Imfinzi for patients with mismatch repair proficient
disease. (DUO-E, August 2024)
|
|
Priority Review
|
US
|
|
Imfinzi for limited-stage
small cell lung cancer whose disease has not progressed following
platinum-based concurrent chemoradiotherapy. (ADRIATIC, August
2024)
|
|
Approval
|
US
|
|
Imfinzi in combination
with chemotherapy for the treatment of adult patients with
resectable early-stage (IIA-IIIB) NSCLC and no
known EGFR mutations or ALK rearrangements. (AEGEAN, August
2024)
|
|
Phase III presentation: ESMO
|
NIAGARA
|
|
In a planned interim analysis, patients treated with
the Imfinzi perioperative regimen showed a 32% reduction
in the risk of disease progression, recurrence, not undergoing
surgery, or death versus the comparator arm (EFS HR 0.68; 95% CI
0.56-0.82, p<0.0001). Estimated median EFS was not yet reached
for the Imfinzi arm versus 46.1 months for the comparator
arm. In addition, Imfinzi perioperative regimen reduced the risk of
death by 25% versus neoadjuvant chemotherapy with radical
cystectomy (OS HR 0.75; 95% CI 0.59-0.93, p=0.0106). (September
2024)
|
|
Phase III presentation: ESMO
|
HIMALAYA
|
|
At five years of follow-up, latest exploratory analysis of HIMALAYA
showed that a single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen (Single Tremelimumab
Regular Interval Durvalumab), reduced the risk of death by 24%
compared to sorafenib (HR 0.76, 95% CI 0.65-0.89). An estimated
19.6% of patients treated with the STRIDE regimen were alive at
five years versus 9.4% of those treated with sorafenib. (September
2024)
|
Lynparza
|
Event
|
|
|
Commentary
|
|
Approval
|
Europe
|
|
Imfinzi plus chemotherapy
as 1st-line treatment followed by Lynparza and Imfinzi for patients with mismatch repair proficient
disease. (DUO-E, August 2024)
|
Enhertu
|
Event
|
|
|
Commentary
|
|
Approval
|
China
|
|
Conditional approval as monotherapy for the treatment of adult
patients with locally advanced or metastatic HER2-positive gastric
or gastroesophageal junction adenocarcinoma who have received two
or more prior treatment regimens. (DESTINY-Gastric06, August
2024)
|
|
Phase IIIb/IV presentation: ESMO
|
DESTINY-Breast12
|
|
Enhertu demonstrated
substantial overall and intracranial clinical activity in a large
cohort of patients with HER2-positive metastatic breast cancer who
have brain metastases and received no more than two prior lines of
therapy in the metastatic setting with a 12-month PFS rate of
61.6%. (September 2024)
|
|
Priority Review
|
US
|
|
For the treatment of adult patients with unresectable or metastatic
HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with
membrane staining) breast cancer who have received at least one
endocrine therapy in the metastatic setting. (DESTINY-Breast06,
October 2024)
|
|
Approval
|
China
|
|
Conditional approval as monotherapy for the treatment of adult
patients with unresectable, locally advanced or metastatic NSCLC
whose tumours have activating HER2 mutations and who have received a prior
systemic therapy. (DESTINY-Lung02, DESTINY-Lung05, October
2024)
|
Calquence
|
Event
|
|
|
Commentary
|
|
Phase III trial readout
|
AMPLIFY
|
|
Interim analysis of AMPLIFY Phase III trial showed a fixed duration
of Calquence in combination with venetoclax, with or
without obinutuzumab, demonstrated a statistically significant and
clinically meaningful improvement in PFS compared to
standard-of-care chemoimmunotherapy in previously untreated adult
patients with chronic lymphocytic leukaemia. (July
2024)
|
|
Priority Review
|
US
|
|
For the treatment of adult patients with previously untreated
mantle cell lymphoma. (ECHO, October 2024)
|
Datopotamab deruxtecan (Dato-DXd)
|
Event
|
|
|
Commentary
|
|
Phase III presentation: WCLC
|
TROPION-Lung01
|
|
Exploratory analysis of the TROPION-Lung01 Phase III trial showed
TROP2 as measured by AstraZeneca's proprietary computational
pathology platform, quantitative continuous scoring, was predictive
of clinical outcomes in patients with advanced or metastatic NSCLC
who were treated with Dato-DXd. (September 2024)
|
|
Phase III presentation: WCLC
|
TROPION-Lung01
|
|
Demonstrated a clinically meaningful, but not statistically
significant, trend toward improving OS with Dato-DXd compared to
docetaxel in patients with locally advanced or metastatic
non-squamous NSCLC treated with at least one prior line of therapy
(14.6 versus 12.3 months; HR 0.84; 95% CI 0.68-1.05). In the
overall trial population, OS results numerically favoured Dato-DXd
compared to docetaxel (12.9 versus 11.8 months) but did not reach
statistical significance (HR 0.94, 95% CI 0.78-1.14, p=0.530).
(September 2024)
|
|
Phase III trial readout
|
TROPION-Breast01
|
|
TROPION-Breast01 Phase III trial of Dato-DXd compared to
investigator's choice of chemotherapy, which previously met the
dual primary endpoint of PFS, did not achieve statistical
significance in the final OS analysis in patients with inoperable
or metastatic hormone receptor-positive, HER2-low or negative (IHC
0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated with
endocrine-based therapy and at least one systemic therapy.
(September 2024)
|
|
Regulatory update
|
US
|
|
Submission of a new Biologics License Application for accelerated
approval for Dato-DXd for the treatment of adult patients with
locally advanced or metastatic EGFRm NSCLC who have received prior systemic
therapies, including an EGFR-directed therapy. Voluntarily
withdrawal of the Biologics License Application for Dato-DXd for
patients with advanced or metastatic non-squamous NSCLC based on
the TROPION-Lung01 Phase III trial. An additional trial in
biomarker-positive patients in the 2nd line non-squamous NSCLC
setting is also planned. (TROPION-Lung05, TROPION-PanTumor01,
TROPION-Lung01, November 2024)
|
Zoladex
|
Event
|
|
|
Commentary
|
|
Approval
|
China
|
|
Zoladex 10.8mg for breast
cancer in pre- and perimenopausal women suitable for hormonal
manipulation. (Study 11, October 2024)
|
BioPharmaceuticals - CVRM
Wainua
|
Event
|
|
|
Commentary
|
|
CHMP positive opinion
|
EU
|
|
For the treatment of hereditary transthyretin-mediated amyloidosis
in adult patients with stage 1 or stage 2 polyneuropathy, commonly
referred to as hATTR-PN or ATTRv-PN. (NEURO-TTRansform, October
2024)
|
BioPharmaceuticals - R&I
Airsupra
|
Event
|
|
|
Commentary
|
|
Phase III trial readout
|
BATURA
|
|
Interim analysis of the Phase IIIb BATURA trial
showed Airsupra met the primary endpoint, demonstrating a
statistically significant and clinically meaningful reduction in
the risk of a severe exacerbation when used as an as-needed rescue
medication in response to symptoms compared to as-needed albuterol.
(October 2024)
|
Breztri
|
Event
|
|
|
Commentary
|
|
Clinical program completion
|
NGP
|
|
Completion of the clinical programme to support the transition
of Breztri to next-generation propellant with near-zero
Global Warming Potential. (September 2024) A Marketing
Authorisation Application for Breztri with the next-generation propellant has been
accepted by the European Medicines Agency (November
2024). Additional submissions
in the UK and China expected before the end of
2024. (November
2024)
|
Fasenra
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
For the treatment of adult patients with eosinophilic
granulomatosis with polyangiitis. (MANDARA, September
2024)
|
|
CHMP positive opinion
|
EU
|
|
As an add-on treatment for adult patients with relapsing or
refractory eosinophilic granulomatosis with polyangiitis. (MANDARA,
September 2024)
|
|
Approval
|
China
|
|
For maintenance treatment of patients 12 years of age and older
with severe eosinophilic asthma. (MIRACLE, August 2024)
|
|
Phase III trial update
|
ORCHID
|
|
The Phase III ORCHID trial assessing Fasenra in chronic rhinosinusitis with nasal polyps
and asthma did not meet the primary endpoints of improvement in the
size of nasal polyps and in nasal blockage. The safety and
tolerability profile for Fasenra in the trial was consistent with the known
profile of the treatment. Results from ORCHID will be shared with
the scientific community in the future. (November
2024)
|
Tezspire
|
Event
|
|
|
Commentary
|
|
Phase III trial readout
|
WAYPOINT
|
|
Tezspire met both
co-primary endpoints, demonstrating a statistically significant and
clinically meaningful reduction in nasal polyp size and improved
nasal congestion compared to placebo. (November
2024)
|
BioPharmaceuticals - V&I
FluMist
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
For self-administration by adults up to 49 years of age or as
administered by a parent/caregiver to individuals 2-17 years of
age. FluMist is the only influenza vaccine approved for
self-administration in the US. (September 2024)
|
Rare Disease
Alexion, AstraZeneca Rare Disease, presented data from its leading
gMG portfolio at the American Association of Neuromuscular &
Electrodiagnostic Medicine Annual Meeting and the Myasthenia Gravis
Foundation of America Scientific Session in October
2024.
The company presented 11 abstracts, spanning clinical and
real-world data, which add to the extensive body of evidence
supporting the safety and efficacy of Ultomiris and Soliris in treating anti-acetylcholine receptor
antibody-positive gMG, and offer new insights to inform clinical
practice.
Koselugo
|
Event
|
|
|
Commentary
|
|
Phase III trial readout
|
KOMET
|
|
Positive high-level results of the Phase III KOMET trial in adults
with NF1-PN showed that Koselugo met its primary endpoint demonstrating a
statistically significant and clinically meaningful ORR versus
placebo in these adult patients. (November
2024)
|
Interim financial statements
Table 18:
Condensed consolidated statement of comprehensive income: 9M
2024
|
For the nine months ended 30 September
|
|
2024
|
2023
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
39,182
|
33,787
|
|
Product Sales
|
|
37,576
|
32,466
|
|
Alliance Revenue
|
|
1,498
|
1,004
|
|
Collaboration Revenue
|
|
108
|
317
|
|
Cost of sales
|
|
(7,482)
|
(5,960)
|
|
Gross profit
|
|
31,700
|
27,827
|
|
Distribution expense
|
|
(412)
|
(394)
|
|
Research and development expense
|
|
(8,906)
|
(7,862)
|
|
Selling, general and administrative expense
|
|
(14,567)
|
(13,845)
|
|
Other operating income and expense
|
|
152
|
1,233
|
|
Operating profit
|
|
7,967
|
6,959
|
|
Finance income
|
|
394
|
236
|
|
Finance expense
|
|
(1,313)
|
(1,181)
|
|
Share of after tax losses in associates and joint
ventures
|
|
(23)
|
(12)
|
|
Profit before tax
|
|
7,025
|
6,002
|
|
Taxation
|
|
(1,484)
|
(1,000)
|
|
Profit for the period
|
|
5,541
|
5,002
|
|
Other comprehensive income:
|
|
|
|
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
Remeasurement of the defined benefit pension liability
|
|
136
|
(1)
|
|
Net gains on equity investments measured at fair value through
other comprehensive income
|
|
264
|
45
|
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
|
12
|
5
|
|
Tax on items that will not be reclassified to profit or
loss
|
|
(50)
|
-
|
|
|
|
362
|
49
|
|
Items that may be reclassified subsequently to profit or
loss:
|
|
|
|
|
Foreign exchange arising on consolidation
|
|
543
|
(201)
|
|
Foreign exchange arising on designated liabilities in net
investment hedges
|
|
(84)
|
(63)
|
|
Fair value movements on cash flow hedges
|
|
(42)
|
62
|
|
Fair value movements on cash flow hedges transferred to profit and
loss
|
|
1
|
28
|
|
Fair value movements on derivatives designated in net investment
hedges
|
|
13
|
47
|
|
Gains/(costs) of hedging
|
|
2
|
(3)
|
|
Tax on items that may be reclassified subsequently to profit or
loss
|
|
16
|
(7)
|
|
|
|
449
|
(137)
|
|
Other comprehensive income/(expense), net of tax
|
|
811
|
(88)
|
|
Total comprehensive income for the period
|
|
6,352
|
4,914
|
|
Profit attributable to:
|
|
|
|
|
Owners of the Parent
|
|
5,535
|
4,995
|
|
Non-controlling interests
|
|
6
|
7
|
|
|
|
5,541
|
5,002
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners of the Parent
|
|
6,346
|
4,907
|
|
Non-controlling interests
|
|
6
|
7
|
|
|
|
6,352
|
4,914
|
|
Basic earnings per $0.25 Ordinary Share
|
|
$3.57
|
$3.22
|
|
Diluted earnings per $0.25 Ordinary Share
|
|
$3.54
|
$3.20
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
|
1,550
|
1,549
|
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
|
1,562
|
1,560
|
Table 19:
Condensed consolidated statement of comprehensive income: Q3
2024
|
For the quarter ended 30 September
|
|
|
|
|
|
|
2024
|
2023
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
13,565
|
11,492
|
|
Product Sales
|
|
12,947
|
11,018
|
|
Alliance Revenue
|
|
559
|
377
|
|
Collaboration Revenue
|
|
59
|
97
|
|
Cost of sales
|
|
(3,081)
|
(2,095)
|
|
Gross profit
|
|
10,484
|
9,397
|
|
Distribution expense
|
|
(145)
|
(129)
|
|
Research and development expense
|
|
(3,115)
|
(2,584)
|
|
Selling, general and administrative expense
|
|
(5,143)
|
(4,800)
|
|
Other operating income and expense
|
|
25
|
70
|
|
Operating profit
|
|
2,106
|
1,954
|
|
Finance income
|
|
183
|
101
|
|
Finance expense
|
|
(457)
|
(392)
|
|
Share of after tax losses in associates and joint
ventures
|
|
(4)
|
(11)
|
|
Profit before tax
|
|
1,828
|
1,652
|
|
Taxation
|
|
(395)
|
(274)
|
|
Profit for the period
|
|
1,433
|
1,378
|
|
Other comprehensive income:
|
|
|
|
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
Remeasurement of the defined benefit pension liability
|
|
35
|
(8)
|
|
Net gains on equity investments measured at fair value through
other comprehensive income
|
|
175
|
93
|
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
|
-
|
1
|
|
Tax on items that will not be reclassified to profit or
loss
|
|
(23)
|
5
|
|
|
|
187
|
91
|
|
Items that may be reclassified subsequently to profit or
loss:
|
|
|
|
|
Foreign exchange arising on consolidation
|
|
1,097
|
(306)
|
|
Foreign exchange arising on designated liabilities in net
investment hedges
|
|
12
|
38
|
|
Fair value movements on cash flow hedges
|
|
96
|
(27)
|
|
Fair value movements on cash flow hedges transferred to profit and
loss
|
|
(101)
|
99
|
|
Fair value movements on derivatives designated in net investment
hedges
|
|
(32)
|
7
|
|
Costs of hedging
|
|
(12)
|
(2)
|
|
Tax on items that may be reclassified subsequently to profit or
loss
|
|
(22)
|
(19)
|
|
|
|
1,038
|
(210)
|
|
Other comprehensive income/(expense), net of tax
|
|
1,225
|
(119)
|
|
Total comprehensive income for the period
|
|
2,658
|
1,259
|
|
Profit attributable to:
|
|
|
|
|
Owners of the Parent
|
|
1,429
|
1,374
|
|
Non-controlling interests
|
|
4
|
4
|
|
|
|
1,433
|
1,378
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners of the Parent
|
|
2,654
|
1,255
|
|
Non-controlling interests
|
|
4
|
4
|
|
|
|
2,658
|
1,259
|
|
Basic earnings per $0.25 Ordinary Share
|
|
$0.92
|
$0.89
|
|
Diluted earnings per $0.25 Ordinary Share
|
|
$0.91
|
$0.88
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
|
1,550
|
1,549
|
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
|
1,562
|
1,560
|
Table 20:
Condensed consolidated statement of financial
position
|
|
|
At 30 Sep
2024
|
At 31 Dec
2023
|
At 30 Sep
2023
|
|
|
|
$m
|
$m
|
$m
|
|
Assets
Non-current assets
|
|
|
|
|
|
Property, plant and equipment
|
|
10,135
|
9,402
|
8,723
|
|
Right-of-use assets
|
|
1,378
|
1,100
|
977
|
|
Goodwill
|
|
21,139
|
20,048
|
19,939
|
|
Intangible assets
|
|
39,394
|
38,089
|
37,687
|
|
Investments in associates and joint ventures
|
|
290
|
147
|
62
|
|
Other investments
|
|
1,855
|
1,530
|
1,228
|
|
Derivative financial instruments
|
|
319
|
228
|
151
|
|
Other receivables
|
|
915
|
803
|
761
|
|
Deferred tax assets
|
|
5,342
|
4,718
|
4,057
|
|
|
|
80,767
|
76,065
|
73,585
|
|
Current assets
|
|
|
|
|
|
Inventories
|
|
5,662
|
5,424
|
5,292
|
|
Trade and other receivables
|
|
11,879
|
12,126
|
11,300
|
|
Other investments
|
|
133
|
122
|
244
|
|
Derivative financial instruments
|
|
16
|
116
|
97
|
|
Income tax receivable
|
|
1,668
|
1,426
|
697
|
|
Cash and cash equivalents
|
|
4,797
|
5,840
|
4,871
|
|
|
|
24,155
|
25,054
|
22,501
|
|
Total assets
|
|
104,922
|
101,119
|
96,086
|
|
Liabilities
Current liabilities
|
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(1,253)
|
(5,129)
|
(5,372)
|
|
Lease liabilities
|
|
(317)
|
(271)
|
(235)
|
|
Trade and other payables
|
|
(21,684)
|
(22,374)
|
(20,542)
|
|
Derivative financial instruments
|
|
(17)
|
(156)
|
(83)
|
|
Provisions
|
|
(1,187)
|
(1,028)
|
(1,193)
|
|
Income tax payable
|
|
(1,468)
|
(1,584)
|
(1,163)
|
|
|
|
(25,926)
|
(30,542)
|
(28,588)
|
|
Non-current liabilities
|
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(28,887)
|
(22,365)
|
(22,225)
|
|
Lease liabilities
|
|
(1,105)
|
(857)
|
(744)
|
|
Derivative financial instruments
|
|
(34)
|
(38)
|
(75)
|
|
Deferred tax liabilities
|
|
(3,568)
|
(2,844)
|
(2,752)
|
|
Retirement benefit obligations
|
|
(1,361)
|
(1,520)
|
(1,048)
|
|
Provisions
|
|
(1,063)
|
(1,127)
|
(1,189)
|
|
Income tax payable
|
|
(174)
|
-
|
-
|
|
Other payables
|
|
(1,999)
|
(2,660)
|
(2,244)
|
|
|
|
(38,191)
|
(31,411)
|
(30,277)
|
|
Total liabilities
|
|
(64,117)
|
(61,953)
|
(58,865)
|
|
Net assets
|
|
40,805
|
39,166
|
37,221
|
|
Equity
Capital and reserves attributable to equity holders of the
Parent
|
|
|
||
|
Share capital
|
|
388
|
388
|
387
|
|
Share premium account
|
|
35,203
|
35,188
|
35,166
|
|
Other reserves
|
|
1,990
|
2,065
|
2,078
|
|
Retained earnings
|
|
3,138
|
1,502
|
(434)
|
|
|
|
40,719
|
39,143
|
37,197
|
|
Non-controlling interests
|
|
86
|
23
|
24
|
|
Total equity
|
|
40,805
|
39,166
|
37,221
|
Table 21: Condensed consolidated statement of changes in
equity
|
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 Jan 2023
|
|
387
|
35,155
|
2,069
|
(574)
|
37,037
|
21
|
37,058
|
|
Profit for the period
|
|
-
|
-
|
-
|
4,995
|
4,995
|
7
|
5,002
|
|
Other comprehensive expense
|
|
-
|
-
|
-
|
(88)
|
(88)
|
-
|
(88)
|
|
Transfer to other reserves
|
|
-
|
-
|
9
|
(9)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(4,487)
|
(4,487)
|
-
|
(4,487)
|
|
Dividends paid to non-controlling interests
|
|
-
|
-
|
-
|
-
|
-
|
(4)
|
(4)
|
|
Issue of Ordinary Shares
|
|
-
|
11
|
-
|
-
|
11
|
-
|
11
|
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
429
|
429
|
-
|
429
|
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(700)
|
(700)
|
-
|
(700)
|
|
Net movement
|
|
-
|
11
|
9
|
140
|
160
|
3
|
163
|
|
At 30 Sep 2023
|
|
387
|
35,166
|
2,078
|
(434)
|
37,197
|
24
|
37,221
|
|
|
|
|
|
|
|
|
|
|
|
At 1 Jan 2024
|
|
388
|
35,188
|
2,065
|
1,502
|
39,143
|
23
|
39,166
|
|
Profit for the period
|
|
-
|
-
|
-
|
5,535
|
5,535
|
6
|
5,541
|
|
Other comprehensive income
|
|
-
|
-
|
-
|
811
|
811
|
-
|
811
|
|
Transfer to other reserves
|
|
-
|
-
|
1
|
(1)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(4,602)
|
(4,602)
|
-
|
(4,602)
|
|
Dividends paid to non-controlling interests
|
|
-
|
-
|
-
|
-
|
-
|
(4)
|
(4)
|
|
Issue of Ordinary Shares
|
|
-
|
15
|
-
|
-
|
15
|
-
|
15
|
|
Changes in non-controlling interests
|
|
-
|
-
|
-
|
-
|
-
|
61
|
61
|
|
Movement in shares held by Employee Benefit Trust
|
|
-
|
-
|
(76)
|
-
|
(76)
|
-
|
(76)
|
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
487
|
487
|
-
|
487
|
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(594)
|
(594)
|
-
|
(594)
|
|
Net movement
|
|
-
|
15
|
(75)
|
1,636
|
1,576
|
63
|
1,639
|
|
At 30 Sep 2024
|
|
388
|
35,203
|
1,990
|
3,138
|
40,719
|
86
|
40,805
|
Table 22:
Condensed consolidated statement of cash flows: 9M
2024
|
For the nine months ended 30 September
|
|
2024
|
2023
|
|
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
|
|
Profit before tax
|
|
7,025
|
6,002
|
|
Finance income and expense
|
|
919
|
945
|
|
Share of after tax losses of associates and joint
ventures
|
|
23
|
12
|
|
Depreciation, amortisation and impairment
|
|
4,351
|
4,060
|
|
Movement in working capital and short-term provisions
|
|
(543)
|
150
|
|
Gains on disposal of intangible assets
|
|
(34)
|
(247)
|
|
Fair value movements on contingent consideration arising from
business combinations
|
|
251
|
202
|
|
Non-cash
and other movements
|
|
15
|
(623)
|
|
Cash generated from operations
|
|
12,007
|
10,501
|
|
Interest paid
|
|
(1,075)
|
(826)
|
|
Tax paid
|
|
(1,978)
|
(1,710)
|
|
Net cash inflow from operating activities
|
|
8,954
|
7,965
|
|
Cash flows from investing activities
|
|
|
|
|
Acquisition of subsidiaries, net of cash acquired
|
|
(2,771)
|
(189)
|
|
Payments upon vesting of employee share awards attributable to
business combinations
|
|
-
|
(84)
|
|
Payment of contingent consideration from business
combinations
|
|
(737)
|
(610)
|
|
Purchase of property, plant and equipment
|
|
(1,216)
|
(836)
|
|
Disposal of property, plant and equipment
|
|
53
|
131
|
|
Purchase of intangible assets
|
|
(2,415)
|
(1,996)
|
|
Disposal of intangible assets
|
|
107
|
288
|
|
Movement in profit-participation liability
|
|
-
|
190
|
|
Purchase of non-current asset investments
|
|
(96)
|
(109)
|
|
Disposal of non-current asset investments
|
|
73
|
32
|
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
|
67
|
(12)
|
|
Payments to associates and joint ventures
|
|
(158)
|
-
|
|
Disposal of investments in associates and joint
ventures
|
|
13
|
-
|
|
Interest received
|
|
281
|
208
|
|
Net cash (outflow) from investing activities
|
|
(6,799)
|
(2,987)
|
|
Net cash inflow before financing activities
|
|
2,155
|
4,978
|
|
Cash flows from financing activities
|
|
|
|
|
Proceeds from issue of share capital
|
|
15
|
12
|
|
Own shares purchased by Employee Benefit Trust
|
|
(81)
|
-
|
|
Issue of loans and borrowings
|
|
6,492
|
3,816
|
|
Repayment of loans and borrowings
|
|
(4,647)
|
(4,655)
|
|
Dividends paid
|
|
(4,626)
|
(4,479)
|
|
Hedge contracts relating to dividend payments
|
|
16
|
(19)
|
|
Repayment of obligations under leases
|
|
(233)
|
(194)
|
|
Movement in short-term borrowings
|
|
572
|
110
|
|
Payment of Acerta Pharma share purchase liability
|
|
(833)
|
(867)
|
|
Net cash (outflow) from financing activities
|
|
(3,325)
|
(6,276)
|
|
Net (decrease) in Cash and cash equivalents in the
period
|
|
(1,170)
|
(1,298)
|
|
Cash and cash equivalents at the beginning of the
period
|
|
5,637
|
5,983
|
|
Exchange rate effects
|
|
(32)
|
(66)
|
|
Cash and cash equivalents at the end of the period
|
|
4,435
|
4,619
|
|
Cash and cash equivalents consist of:
|
|
|
|
|
Cash and cash equivalents
|
|
4,797
|
4,871
|
|
Overdrafts
|
|
(362)
|
(252)
|
|
|
|
4,435
|
4,619
|
Notes to the Interim financial statements
Note 1: Basis of preparation and accounting policies
These unaudited condensed
consolidated
Interim financial statements for the nine months ended 30 September
2024 have been prepared in accordance with International Accounting
Standard 34, 'Interim Financial Reporting' (IAS 34), as issued by
the International Accounting Standards Board (IASB), IAS 34 as
adopted by the European Union, UK-adopted IAS 34 and the Disclosure
Guidance and Transparency Rules sourcebook of the United Kingdom's
Financial Conduct Authority and with the requirements of the
Companies Act 2006 as applicable to companies reporting under those
standards.
The unaudited Interim financial statements for the nine months
ended 30 September 2024 were approved by the Board of Directors for
publication on 12 November 2024.
This results announcement does not constitute statutory accounts of
the Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The annual financial statements of the Group
for the year ended 31 December 2023 were prepared in accordance
with UK-adopted international accounting standards and with the
requirements of the Companies Act 2006. The annual financial
statements also comply fully with IFRS Accounting Standards as
issued by the IASB and International Accounting Standards as
adopted by the European Union. Except for the estimation of the
interim income tax charge, the Interim financial statements have
been prepared applying the accounting policies that were applied in
the preparation of the Group's published consolidated financial
statements for the year ended 31 December 2023.
The comparative figures for the financial year ended 31 December
2023 are not the Group's statutory accounts for that financial
year. Those accounts have been reported on by the Group's auditors
and have been delivered to the Registrar of Companies; their report
was (i) unqualified, (ii) did not include a reference to any
matters to which the auditors drew attention by way of emphasis
without qualifying their report, and (iii) did not contain a
statement under section 498(2) or (3) of the Companies Act
2006.
Going concern
The Group has considerable financial resources available. As at 30
September 2024, the Group has $11.7bn in financial resources (cash
and cash equivalent balances of $4.8bn and undrawn committed bank
facilities of $6.9bn, with $1.6bn of borrowings due within one
year). These facilities contain no financial covenants and were
undrawn at 30 September 2024. There are $4.9bn of undrawn committed
bank facilities are available until April 2029. Additionally, there
are a further $2.0bn undrawn committed bank facilities available
until February 2025.
The Group's revenues are largely derived from sales of medicines
covered by patents, which provide a relatively high level of
resilience and predictability to cash inflows, although government
price interventions in response to budgetary constraints are
expected to continue to adversely affect revenues in some of our
significant markets. The Group, however, anticipates new revenue
streams from both recently launched medicines and those in
development, and the Group has a wide diversity of customers and
suppliers across different geographic areas.
Consequently, the Directors believe that, overall, the Group is
well placed to manage its business risks successfully. Accordingly,
they continue to adopt the going concern basis in preparing the
Interim financial statements.
Legal proceedings
The information contained in Note 6 updates the disclosures
concerning legal proceedings and contingent liabilities in the
Group's Annual Report and Form
20-F Information 2023.
Employee Benefit Trust
Following an amendment to the Employee Benefit Trust (EBT) Deed on
10 June 2024, AstraZeneca obtained control and commenced
consolidation of the EBT. Accordingly, cash paid on purchases of
AstraZeneca Ordinary shares or American Depositary Receipts is
presented within Financing activities in the Cash flow
statement.
Note 2: Intangible assets
In accordance with IAS 36 'Impairment of Assets', reviews for
triggers of impairment or impairment reversals at an individual
asset or cash generating unit level were conducted, and impairment
tests carried out where triggers were identified. Following a
strategic review of our portfolio priorities, the business
decision was made to cease promotional activity
for Andexxa resulting in impairment charges of $504m
recorded against the Andexxa intangible asset under value in use model
applying a discount rate of 7.5% (revised carrying amount: $nil),
total net impairment charges of $525m have been recorded against
intangible assets during the nine months ended 30 September 2024
(9M 2023: $376m net charge). In 9M 2023, net impairment charges
included the $244m impairment of the ALXN1840 intangible asset,
following the decision to discontinue this development programme in
Wilson's disease.
The acquisition of Icosavax, Inc. completed on 19 February 2024.
The transaction is recorded as an asset acquisition based on the
concentration test permitted under IFRS 3 'Business Combinations',
with consideration of $841m principally relating to $639m of
intangible assets, $141m of cash and cash equivalents and $51m of
marketable securities. Contingent consideration of up to $300m
could be paid on achievement of regulatory and sales milestones;
these potential liabilities would be recorded when the relevant
recognition event for a regulatory or sales milestone is
achieved.
The acquisition of Amolyt Pharma completed on 15 July 2024. The
transaction is recorded as an asset acquisition based on the
concentration test permitted under IFRS 3 'Business Combinations',
with consideration of $857m principally relating to $800m of
intangible assets and $98m of cash and cash equivalents. Contingent
consideration of up to $250m could be paid on achievement of a
regulatory milestone; this potential liability would be recorded
when the relevant recognition event for a regulatory milestone is
achieved.
Note 3: Net debt
The table below provides an analysis of Net debt and a reconciliation of Net
Cash flow to the movement in Net debt. The Group monitors Net debt
as part of its capital management policy as described in Note 28 of
the Annual Report and Form
20-F Information 2023. Net debt
is a non-GAAP financial measure.
Table 23: Net
debt
|
|
|
At 1 Jan 2024
|
Cash flow
|
Acquisitions
|
Non-cash& other
|
Exchange movements
|
At 30 Sep 2024
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
|
(22,365)
|
(6,499)
|
(3)
|
69
|
(89)
|
(28,887)
|
|
Non-current instalments of leases
|
|
(857)
|
1
|
(12)
|
(233)
|
(4)
|
(1,105)
|
|
Total long-term debt
|
|
(23,222)
|
(6,498)
|
(15)
|
(164)
|
(93)
|
(29,992)
|
|
Current instalments of loans
|
|
(4,614)
|
4,586
|
(9)
|
(3)
|
28
|
(12)
|
|
Current instalments of leases
|
|
(271)
|
271
|
(6)
|
(311)
|
-
|
(317)
|
|
Commercial paper
|
|
-
|
(472)
|
-
|
-
|
-
|
(472)
|
|
Collateral received from derivative counterparties
|
|
(215)
|
(72)
|
-
|
-
|
-
|
(287)
|
|
Other short-term borrowings excluding overdrafts
|
|
(97)
|
(28)
|
-
|
(1)
|
6
|
(120)
|
|
Overdrafts
|
|
(203)
|
(158)
|
-
|
1
|
(2)
|
(362)
|
|
Total current debt
|
|
(5,400)
|
4,127
|
(15)
|
(314)
|
32
|
(1,570)
|
|
Gross borrowings
|
|
(28,622)
|
(2,371)
|
(30)
|
(478)
|
(61)
|
(31,562)
|
|
Net derivative financial instruments
|
|
150
|
41
|
-
|
93
|
-
|
284
|
|
Net borrowings
|
|
(28,472)
|
(2,330)
|
(30)
|
(385)
|
(61)
|
(31,278)
|
|
Cash and cash equivalents
|
|
5,840
|
(1,254)
|
242
|
(1)
|
(30)
|
4,797
|
|
Other investments - current
|
|
122
|
(67)
|
87
|
-
|
(9)
|
133
|
|
Cash and investments
|
|
5,962
|
(1,321)
|
329
|
(1)
|
(39)
|
4,930
|
|
Net debt
|
|
(22,510)
|
(3,651)
|
299
|
(386)
|
(100)
|
(26,348)
|
Net debt increased by $3,838m in the nine months to $26,348m.
Details of the committed undrawn bank facilities are disclosed
within the going concern section of Note 1. Non-cash movements in
the period include fair value adjustments under IFRS 9 'Financial
Instruments'.
In February 2024, AstraZeneca issued the following:
- $1,250m
of fixed-rate notes with a coupon of 4.8% maturing in February
2027
- $1,250m
of fixed-rate notes with a coupon of 4.85% maturing in February
2029
- $1,000m
of fixed-rate notes with a coupon of 4.9% maturing in February
2031
- $1,500m
of fixed-rate notes with a coupon of 5% maturing in February
2034
In August 2024, AstraZeneca issued the following:
- €650m
of fixed-rate notes with a coupon of 3.121% maturing in August
2030
- €750m
of fixed-rate notes with a coupon of 3.278% maturing in August
2033
AstraZeneca repaid two bonds of carrying value $2,569m and floating
rate bank loans of $2,000m during the nine months which are
included in the cash outflow from Repayment of loans and borrowings
of $4,647m.
The Group has agreements with some bank counterparties whereby the
parties agree to post cash collateral on financial derivatives, for
the benefit of the other, equivalent to the market valuation of the
derivative positions above a predetermined threshold. The carrying
value of such cash collateral held by the Group at 30 September
2024 was $287m (31 December 2023: $215m) and the carrying value of
such cash collateral posted by the Group at 30 September 2024 was
$68m (31 December 2023: $102m).
The equivalent GAAP measure to Net debt is 'liabilities arising
from financing activities', which excludes the amounts for cash and
overdrafts, other investments and non-financing derivatives shown
above and includes the Acerta Pharma share purchase liability of
$nil (31 December 2023: $833m).
During the quarter ended 30 September 2024, Standard and Poor's
upgraded the Company's solicited long term credit rating to A+ from
A. The short term rating remained at A-1. There were no changes to
Moody's credit ratings (long term: A2; short term:
P-1).
Note 4: Financial Instruments
As detailed in the Group's most recent annual financial statements,
the principal financial instruments consist of derivative financial
instruments, other investments, trade and other receivables, cash
and cash equivalents, trade and other payables, lease liabilities
and interest-bearing loans and borrowings.
The Group has certain equity investments that are categorised as
Level 3 in the fair value hierarchy that are held at $370m (31
December 2023: $313m) and for which a fair value gain of $nil has
been recognised in the nine months ended 30 September 2024 (9M
2023: $17m). In the absence of specific market data, these unlisted
investments are held at fair value based on the cost of investment
and adjusted as necessary for impairments and revaluations on new
funding rounds, which are seen to approximate the fair value. All
other fair value gains and/or losses that are presented in Net
gains on equity investments measured at fair value through other
comprehensive income, in the Condensed consolidated statement of
comprehensive income for the nine months ended 30 September 2024,
are Level 1 fair value measurements, valued based on quoted prices
in active markets.
Financial instruments measured at fair value include $1,920m of
other investments, $3,408m held in money-market funds and $284m of
derivatives as at 30 September 2024. With the exception of
derivatives being Level 2 fair valued, and certain equity
instruments of $379m categorised as Level 3, the aforementioned
balances are Level 1 fair valued. Financial instruments measured at
amortised cost include $68m of cash collateral pledged to
counterparties. The total fair value of interest-bearing loans and
borrowings at 30 September 2024, which have a carrying value of
$31,562m in the Condensed consolidated statement of financial
position, was $31,396m.
Table 24:
Financial instruments - contingent
consideration
|
|
|
2024
|
|
2023
|
|
|
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
|
1,945
|
192
|
2,137
|
2,222
|
|
Additions through business combinations
|
|
-
|
198
|
198
|
60
|
|
Settlements
|
|
(736)
|
(1)
|
(737)
|
(610)
|
|
Revaluations
|
|
220
|
32
|
252
|
202
|
|
Discount unwind
|
|
77
|
8
|
85
|
99
|
|
At 30 September
|
|
1,506
|
429
|
1,935
|
1,973
|
Contingent consideration arising from business combinations is fair
valued using decision-tree analysis, with key inputs including the
probability of success, consideration of potential delays and the
expected levels of future revenues.
The contingent consideration balance relating to BMS's share of the
global diabetes alliance of $1,506m (31 December 2023:
$1,945m) would increase/decrease by $151m with an increase/decrease
in sales of 10%, as compared with the current
estimates.
Note 5: Business combinations
Gracell
On 22 February 2024, AstraZeneca completed the acquisition of
Gracell Biotechnologies Inc. (Gracell), a global clinical-stage
biopharmaceutical company developing innovative cell therapies for
the treatment of cancer and autoimmune diseases.
The purchase price allocation review has been completed, currently
there are no changes to the amounts reported in the H1 and Q2 2024
results announcement. The transaction is recorded as a business
combination using the acquisition method of accounting in
accordance with IFRS 3 'Business Combinations'.
The total consideration fair value of $1,037m includes cash
consideration of $983m and future regulatory milestone-based
consideration of $54m. Intangible assets recognised relate to
products in development, principally AZD0120. Goodwill of $136m has
been recognised. Gracell's results have been consolidated
into the Group's results from 22 February 2024.
Fusion
On 4 June 2024, AstraZeneca completed the acquisition of Fusion
Pharmaceuticals Inc., (Fusion) a clinical-stage biopharmaceutical
company developing next-generation radioconjugates.
The purchase price allocation review has been completed, currently
there are no changes to the amounts reported in the H1 and Q2 2024
results announcement. The transaction is recorded as a business
combination using the acquisition method of accounting in
accordance with IFRS 3 'Business Combinations'.
The total consideration fair value of $2,195m includes cash
consideration of $2,051m and future regulatory milestone-based
consideration of $144m. Intangible assets relating to products in
development comprise the FPI-2265 ($848m), FPI-2059 ($165m) and
AZD2068 ($313m) programmes. Goodwill of $947m has been recognised.
Fusion's results have been consolidated into the Group's results
from 4 June 2024.
Note 6: Legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered
typical to its business, including litigation and investigations,
including Government investigations, relating to product liability,
commercial disputes, infringement of intellectual property (IP)
rights, the validity of certain patents, anti-trust law and sales
and marketing practices. The matters discussed below constitute the
more significant developments since publication of the disclosures
concerning legal proceedings in the Company's Annual Report and
Form 20-F Information 2023 and the Interim Financial
Statements for the six months ended 30 June 2024 (the
Disclosures). Information about the nature and facts of the cases
is disclosed in accordance with IAS 37.
As discussed in the Disclosures, the majority of claims involve
highly complex issues. Often these issues are subject to
substantial uncertainties and, therefore, the probability of a
loss, if any, being sustained and/or an estimate of the amount of
any loss is difficult to ascertain.
In cases that have been settled or adjudicated, or where
quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able
to make a reasonable estimate of the loss, AstraZeneca records the
loss absorbed or makes a provision for its best estimate of the
expected loss. The position could change over time and the
estimates that the Company made, and upon which the Company have
relied in calculating these provisions are inherently imprecise.
There can, therefore, be no assurance that any losses that result
from the outcome of any legal proceedings will not exceed the
amount of the provisions that have been booked in the accounts. The
major factors causing this uncertainty are described more fully in
the Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and
enforce, its IP.
Matters disclosed in respect of the third quarter of 2024 and to 12
November 2024
Table 25: Patent
litigation
|
Legal proceedings brought against AstraZeneca
|
||
|
Faslodex patent
proceedings, Japan
Considered to be a contingent asset
|
|
∗ In 2021 in Japan, AstraZeneca
received notice from the Japan Patent Office (JPO) that Sandoz K.K.
(Sandoz) and Sun Pharma Japan Ltd. (Sun) were seeking to invalidate
the Faslodex formulation
patent.
∗ AstraZeneca defended the
challenged patent and Sun withdrew from the JPO patent
challenge.
∗ In July 2023, the JPO issued a
final decision upholding various claims of the challenged patent
and determining that other patent claims were
invalid.
∗ In August 2023, Sandoz
appealed the JPO decision to the Japan IP High Court (High
Court).
∗ In October 2024, the High
Court affirmed the decision by the JPO.
|
|
Tagrisso patent
proceedings, US
Considered to be a contingent liability
|
|
∗ In September 2021, Puma
Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a patent
infringement lawsuit in the US District Court for the District of
Delaware (District Court) against AstraZeneca relating
to Tagrisso.
∗ In March 2024, the District
Court dismissed Puma.
∗ The jury trial, with Wyeth as
the plaintiff, took place in May 2024. The jury found Wyeth's
patents infringed and awarded Wyeth $107.5m in past damages. The
jury also found that the infringement was not wilful.
∗ In proceedings following the
jury award, the District Court rejected AstraZeneca's
indefiniteness and equitable defences but granted judgment as a
matter of law in favour of AstraZeneca on the grounds that the
patents were invalid for lack of written description and
enablement. Wyeth has filed an appeal.
|
|
Legal proceedings brought by AstraZeneca
|
||
|
Lokelma patent
proceedings, US
Considered to be a contingent asset
|
|
∗ In August 2022, in response to
Paragraph IV notices, AstraZeneca initiated ANDA litigation against
multiple generic filers in the US District Court for the District
of Delaware (District Court). AstraZeneca alleged that a generic
version of Lokelma would infringe patents
that are owned or licensed by AstraZeneca.
∗ AstraZeneca has entered into
separate settlement agreements with four generic manufacturers
which resulted in dismissal of the corresponding
litigations.
∗ Additional proceedings with
the remaining generic manufacturer are ongoing in the District
Court. Trial is scheduled for March 2025.
|
|
Soliris patent
proceedings, Canada
Considered to be a contingent asset
|
|
∗ In May 2023, Alexion initiated
patent litigation in Canada alleging that Amgen Pharmaceuticals,
Inc.'s (Amgen) biosimilar eculizumab product will infringe Alexion
patents.
∗ In September 2023, Alexion
initiated patent litigations in Canada alleging that Samsung
Bioepis Co. Ltd.'s (Samsung) biosimilar eculizumab product will
infringe Alexion patents. The filing of the litigation
triggered an automatic 24-month stay of the approval of each
defendant's biosimilar eculizumab product.
∗ Trial against Amgen is
scheduled to begin in January 2025 while trial against Samsung is
scheduled to begin in June 2025.
∗ In July and August 2023, in
Canada, both Amgen and Samsung brought actions challenging the
validity of Alexion's patent relating to the use of eculizumab in
treating aHUS. Trial is scheduled to begin in November
2025.
|
|
Soliris patent
proceedings, US
Matter concluded
|
|
∗ In January 2024, Alexion
initiated patent infringement litigation against Samsung Bioepis
Co. Ltd. (Samsung) in the US District Court for the District of
Delaware (District Court) alleging that Samsung's biosimilar
eculizumab product, for which Samsung is currently seeking FDA
approval, will infringe six Soliris-related patents.
∗ Five of the six asserted
patents were also the subject of inter partes review proceedings
before the US Patent and Trademark Office.
∗ Alexion filed a motion for a
preliminary injunction seeking to enjoin Samsung from launching its
biosimilar eculizumab product upon FDA approval. The District Court
denied Alexion's motion and Alexion appealed that
decision.
∗ In August 2024, the parties
reached resolution of the matter. All legal proceedings in the US
courts have terminated, as have the inter partes review
proceedings.
|
|
Tagrisso patent
proceedings, Russia
Considered to be a contingent asset
|
|
∗ In Russia, in August 2023,
AstraZeneca filed lawsuits in the Arbitration Court of the Moscow
Region (Court) against the Ministry of Health of the Russian
Federation and Axelpharm LLC (Axelpharm) related to Axelpharm's
improper use of AstraZeneca's information to obtain authorisation
to market a generic version of Tagrisso. In December 2023, the Court
dismissed the lawsuit against the Ministry of Health of the Russian
Federation. The appellate court affirmed the dismissal in March
2024. AstraZeneca filed a further appeal, which was dismissed in
July 2024. The lawsuit against Axelpharm was dismissed in September
2024, and AstraZeneca appealed.
∗ In November 2023, Axelpharm
filed a compulsory licensing action against AstraZeneca in the
Court related to a patent that covers Tagrisso. The compulsory licensing
action remains pending. AstraZeneca has also challenged before the
Russian Patent and Trademark Office (PTO) the validity of the
Axelpharm patent on which the compulsory licensing action is
predicated; in August 2024, the PTO determined that Axelpharm's
patent is invalid.
∗ In July 2024, AstraZeneca
filed a patent infringement lawsuit, which remains pending, and an
unfair competition claim with the Federal Anti-Monopoly Service of
Russia (FAS) against AxelPharm and others related to the securing
of state contracts in Russia for its generic version of
Osimertinib.
∗ In August 2024, FAS initiated
an unfair competition case against Axelpharm and OncoTarget based
on AstraZeneca's unfair competition claim.
∗ In November 2024, FAS
determined that Axelpharm had committed unfair competition and that
OncoTarget had not; FAS ordered Axelpharm to cease sales of its
generic osimertinib and pay the Russian government the income it
received from its sales of its generic osimertinib.
|
Table 26: Commercial litigation
|
Legal proceedings brought against AstraZeneca
|
||
|
Amyndas Trade Secrets Litigation, US
Considered to be a contingent liability
|
|
∗ AstraZeneca has been defending
a matter filed by Amyndas Pharmaceuticals Member P.C.
and Amyndas Pharmaceuticals, LLC, in the US District
Court for the District of Massachusetts alleging trade secret
misappropriation and breach of contract claims against Alexion and
Zealand Pharma U.S. Inc. related to Amyndas' C3 inhibitor
candidate.
∗ No trial date has been
set.
|
|
Caelum Trade Secrets Litigation, US
Matter concluded
|
|
∗ AstraZeneca has been defending
a matter filed by the University of Tennessee Research Foundation
in the US District Court for the Eastern District of Tennessee
related to CAEL-101.
∗ In September 2024, the parties
resolved the matter by settlement.
|
|
Seroquel XR Antitrust
Litigation, US
Considered to be a contingent liability
|
|
∗ In 2019, AstraZeneca was named
in several related complaints now proceeding in US District Court
in Delaware (District Court), including several putative class
action lawsuits that were purportedly brought on behalf of classes
of direct purchasers or end payors of Seroquel XR, that allege AstraZeneca
and generic drug manufacturers violated US antitrust laws when
settling patent litigation related to Seroquel XR.
∗ In July 2022, the District
Court dismissed claims relating to one of the generic manufacturers
while allowing claims relating to the second generic manufacturer
to proceed.
∗ In September 2024, AstraZeneca
reached a settlement agreement with one of the plaintiff classes
and the parties are now seeking judicial review and approval of the
settlement.
∗ Trial with the remaining class
of plaintiffs is currently scheduled for May 2025.
|
|
Syntimmune Milestone Litigation, US
Considered to be a contingent liability
|
|
∗ In connection with Alexion's
acquisition of Syntimmune, Inc. (Syntimmune) in December 2020,
Alexion was served with a lawsuit filed by the stockholders'
representative for Syntimmune in Delaware state court that alleged,
among other things, breaches of the 2018 merger
agreement.
∗ The stockholders'
representative alleges that Alexion failed to meet its obligations
under the merger agreement to use commercially reasonable efforts
to achieve the milestones. Alexion also filed a claim for breach of
the representations in the 2018 merger
agreement.
∗ A trial was held in July
2023.
∗ The court issued a partial
decision in September 2024, concluding that the first milestone was
achieved, and that Alexion had breached its contractual obligation
to use commercially reasonable efforts to achieve the milestones.
The court has requested additional briefing regarding damages and
further proceedings regarding Alexion's claim for
breach.
|
|
Viela Bio, Inc. Shareholder Litigation, US
Considered to be a contingent liability
|
|
∗ In February 2023, AstraZeneca
was served with a lawsuit filed in the Delaware state court against
AstraZeneca and certain officers (collectively, Defendants), on
behalf of a putative class of Viela Bio, Inc. (Viela) shareholders.
The complaint alleged that the Defendants breached their fiduciary
duty to Viela shareholders in the course of Viela's 2021 merger
with Horizon Therapeutics, plc.
∗ In July 2024, the Court
granted with prejudice AstraZeneca's motion to
dismiss.
∗ In August 2024, plaintiffs
appealed the dismissal.
|
Table 27: Government investigations and
proceedings
|
Legal proceedings brought by AstraZeneca
|
||
|
340B State Litigation, US
Considered to be a contingent asset
|
|
∗ AstraZeneca has filed lawsuits
against Arkansas, Kansas, Louisiana, Maryland, Minnesota,
Mississippi, Missouri, and West Virginia challenging the
constitutionality of each state's 340B statute.
∗ In the Arkansas matter, trial
is scheduled for April 2025. An intervenor has moved to dismiss
AstraZeneca's complaint.
∗ In the Louisiana matter, the
Court granted the state's motion for summary judgment.
AstraZeneca has filed an appeal.
∗ In the Maryland matter, the
Court has rejected AstraZeneca's preliminary injunction motion. The
state's motion to dismiss remains pending.
∗ In the Minnesota matter, the
state has moved to dismiss AstraZeneca's complaint.
∗ In the Mississippi matter,
AstraZeneca has moved for a preliminary injunction.
∗ The remaining matters are in
their preliminary stages.
|
Other
Additional government inquiries
As is true for most, if not all, major prescription pharmaceutical
companies, AstraZeneca is currently involved in multiple inquiries
into drug marketing and pricing practices. In addition to the
investigations described above, various law enforcement offices
have, from time to time, requested information from the Group.
There have been no material developments in those
matters.
Note 7
Table 28: 9M 2024 - Product Sales year-on-year
analysis[14]
|
|
World
|
US |
Emerging Markets
|
Europe
|
Established RoW
|
|||||||||
|
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
Oncology
|
14,934
|
18
|
21
|
6,870
|
22
|
3,445
|
18
|
28
|
3,000
|
24
|
23
|
1,619
|
(4)
|
4
|
|
Tagrisso
|
4,877
|
11
|
15
|
1,996
|
19
|
1,365
|
8
|
16
|
956
|
16
|
16
|
560
|
(10)
|
(2)
|
|
Imfinzi
|
3,463
|
18
|
22
|
1,883
|
18
|
365
|
37
|
61
|
695
|
30
|
29
|
520
|
(3)
|
6
|
|
Calquence
|
2,321
|
26
|
27
|
1,617
|
21
|
116
|
68
|
90
|
489
|
38
|
38
|
99
|
23
|
27
|
|
Lynparza
|
2,228
|
8
|
10
|
954
|
6
|
475
|
16
|
25
|
612
|
13
|
12
|
187
|
(13)
|
(7)
|
|
Enhertu
|
397
|
n/m
|
n/m
|
-
|
-
|
258
|
n/m
|
n/m
|
92
|
n/m
|
n/m
|
47
|
n/m
|
n/m
|
|
Zoladex
|
817
|
17
|
24
|
11
|
(4)
|
622
|
19
|
28
|
111
|
14
|
13
|
73
|
7
|
15
|
|
Imjudo
|
208
|
30
|
32
|
134
|
25
|
11
|
n/m
|
n/m
|
26
|
n/m
|
n/m
|
37
|
(8)
|
1
|
|
Truqap
|
267
|
n/m
|
n/m
|
260
|
n/m
|
2
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
Orpathys
|
34
|
4
|
7
|
-
|
-
|
34
|
4
|
7
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
322
|
(18)
|
(12)
|
15
|
5
|
197
|
(18)
|
(13)
|
17
|
(34)
|
(34)
|
93
|
(15)
|
(7)
|
|
BioPharmaceuticals: CVRM
|
9,316
|
18
|
21
|
2,221
|
13
|
4,146
|
18
|
24
|
2,385
|
31
|
30
|
564
|
(3)
|
5
|
|
Farxiga
|
5,723
|
31
|
34
|
1,278
|
28
|
2,225
|
35
|
41
|
1,903
|
40
|
39
|
317
|
(9)
|
(1)
|
|
Brilinta
|
992
|
-
|
1
|
543
|
(1)
|
232
|
4
|
11
|
203
|
-
|
(1)
|
14
|
(21)
|
(18)
|
|
Crestor
|
892
|
4
|
9
|
33
|
(18)
|
726
|
7
|
12
|
32
|
(22)
|
(22)
|
101
|
-
|
9
|
|
Seloken/Toprol-XL
|
465
|
(6)
|
(1)
|
-
|
84
|
452
|
(6)
|
(1)
|
10
|
27
|
27
|
3
|
(47)
|
(45)
|
|
Lokelma
|
392
|
31
|
34
|
181
|
16
|
68
|
84
|
90
|
66
|
61
|
61
|
77
|
17
|
30
|
|
roxadustat
|
257
|
23
|
26
|
-
|
-
|
257
|
23
|
26
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Andexxa
|
159
|
24
|
26
|
61
|
7
|
3
|
n/m
|
n/m
|
60
|
38
|
37
|
35
|
25
|
39
|
|
Wainua
|
44
|
n/m
|
n/m
|
44
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
392
|
(27)
|
(26)
|
81
|
(52)
|
183
|
(19)
|
(14)
|
111
|
(16)
|
(15)
|
17
|
11
|
9
|
|
BioPharmaceuticals: R&I
|
5,431
|
20
|
23
|
2,419
|
27
|
1,489
|
13
|
20
|
1,026
|
21
|
20
|
497
|
9
|
14
|
|
Symbicort
|
2,195
|
19
|
22
|
887
|
51
|
653
|
9
|
19
|
415
|
2
|
1
|
240
|
(2)
|
-
|
|
Fasenra
|
1,218
|
7
|
8
|
750
|
4
|
68
|
43
|
52
|
294
|
12
|
11
|
106
|
(1)
|
6
|
|
Pulmicort
|
517
|
5
|
9
|
13
|
(39)
|
427
|
9
|
14
|
51
|
4
|
2
|
26
|
(13)
|
(9)
|
|
Breztri
|
721
|
51
|
53
|
367
|
40
|
199
|
62
|
68
|
102
|
86
|
85
|
53
|
42
|
51
|
|
Tezspire
|
168
|
n/m
|
n/m
|
-
|
-
|
8
|
n/m
|
n/m
|
105
|
n/m
|
n/m
|
55
|
n/m
|
n/m
|
|
Saphnelo
|
327
|
71
|
72
|
294
|
65
|
5
|
n/m
|
n/m
|
17
|
n/m
|
n/m
|
11
|
66
|
82
|
|
Airsupra
|
41
|
n/m
|
n/m
|
41
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
244
|
(26)
|
(25)
|
67
|
(48)
|
129
|
(15)
|
(12)
|
42
|
4
|
3
|
6
|
(13)
|
(11)
|
|
BioPharmaceuticals: V&I
|
680
|
2
|
5
|
201
|
n/m
|
168
|
(7)
|
1
|
189
|
(6)
|
(8)
|
122
|
(48)
|
(44)
|
|
Synagis
|
346
|
(10)
|
(4)
|
(1)
|
n/m
|
168
|
6
|
15
|
80
|
(26)
|
(27)
|
99
|
(15)
|
(7)
|
|
Beyfortus
|
188
|
n/m
|
n/m
|
148
|
n/m
|
-
|
n/m
|
n/m
|
39
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
|
FluMist
|
109
|
40
|
37
|
26
|
61
|
-
|
n/m
|
n/m
|
61
|
5
|
1
|
22
|
n/m
|
n/m
|
|
COVID-19 mAbs
|
31
|
(75)
|
(75)
|
28
|
n/m
|
-
|
n/m
|
n/m
|
3
|
(59)
|
(60)
|
-
|
n/m
|
n/m
|
|
Others
|
6
|
(79)
|
(80)
|
-
|
-
|
-
|
(99)
|
n/m
|
6
|
(43)
|
(45)
|
-
|
n/m
|
n/m
|
|
Rare Disease
|
6,391
|
10
|
14
|
3,842
|
11
|
628
|
29
|
56
|
1,189
|
2
|
1
|
732
|
9
|
18
|
|
Ultomiris
|
2,835
|
32
|
35
|
1,629
|
29
|
92
|
97
|
n/m
|
649
|
31
|
30
|
465
|
37
|
50
|
|
Soliris
|
2,045
|
(16)
|
(11)
|
1,170
|
(11)
|
365
|
8
|
39
|
346
|
(35)
|
(35)
|
164
|
(34)
|
(31)
|
|
Strensiq
|
996
|
18
|
19
|
815
|
18
|
39
|
34
|
48
|
73
|
15
|
14
|
69
|
8
|
18
|
|
Koselugo
|
366
|
49
|
55
|
156
|
9
|
108
|
n/m
|
n/m
|
74
|
93
|
93
|
28
|
81
|
99
|
|
Kanuma
|
149
|
15
|
16
|
72
|
15
|
24
|
(1)
|
7
|
47
|
25
|
25
|
6
|
8
|
16
|
|
Other medicines
|
824
|
(9)
|
(4)
|
87
|
(17)
|
564
|
(3)
|
5
|
75
|
12
|
12
|
98
|
(38)
|
(33)
|
|
Nexium
|
670
|
(9)
|
(2)
|
77
|
(13)
|
458
|
-
|
9
|
40
|
12
|
10
|
95
|
(37)
|
(33)
|
|
Others
|
154
|
(12)
|
(10)
|
10
|
(35)
|
106
|
(13)
|
(10)
|
35
|
13
|
13
|
3
|
(53)
|
(49)
|
|
Total Product Sales
|
37,576
|
16
|
19
|
15,640
|
19
|
10,440
|
16
|
25
|
7,864
|
20
|
20
|
3,632
|
(4)
|
3
|
Table 29: Q3 2024 - Product Sales year-on-year
analysis[15]
|
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|||||||||
|
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
Oncology
|
5,197
|
18
|
21
|
2,484
|
25
|
1,145
|
18
|
28
|
1,032
|
22
|
22
|
536
|
(8)
|
(3)
|
|
Tagrisso
|
1,674
|
14
|
17
|
714
|
24
|
446
|
9
|
16
|
328
|
17
|
17
|
186
|
(6)
|
(1)
|
|
Imfinzi
|
1,203
|
13
|
16
|
680
|
19
|
120
|
40
|
66
|
236
|
16
|
16
|
167
|
(19)
|
(15)
|
|
Calquence
|
813
|
24
|
25
|
570
|
22
|
41
|
47
|
70
|
169
|
32
|
32
|
33
|
11
|
14
|
|
Lynparza
|
778
|
11
|
13
|
347
|
8
|
155
|
18
|
24
|
214
|
21
|
21
|
62
|
(12)
|
(8)
|
|
Enhertu
|
148
|
n/m
|
n/m
|
-
|
-
|
97
|
n/m
|
n/m
|
35
|
n/m
|
n/m
|
16
|
83
|
86
|
|
Zoladex
|
268
|
12
|
18
|
4
|
(34)
|
207
|
14
|
21
|
33
|
8
|
10
|
24
|
16
|
21
|
|
Imjudo
|
72
|
20
|
22
|
46
|
15
|
4
|
n/m
|
n/m
|
10
|
99
|
n/m
|
12
|
(15)
|
(10)
|
|
Truqap
|
125
|
n/m
|
n/m
|
119
|
n/m
|
1
|
-
|
-
|
2
|
-
|
-
|
3
|
-
|
-
|
|
Orpathys
|
10
|
(16)
|
(16)
|
-
|
-
|
10
|
(16)
|
(16)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
106
|
(10)
|
(5)
|
4
|
2
|
64
|
(14)
|
(8)
|
5
|
(27)
|
(26)
|
33
|
(1)
|
5
|
|
BioPharmaceuticals: CVRM
|
3,152
|
17
|
20
|
739
|
7
|
1,396
|
20
|
25
|
826
|
26
|
26
|
191
|
9
|
14
|
|
Farxiga
|
1,938
|
25
|
27
|
411
|
12
|
750
|
30
|
35
|
670
|
32
|
32
|
107
|
4
|
8
|
|
Brilinta
|
327
|
(1)
|
(1)
|
189
|
(2)
|
66
|
3
|
6
|
67
|
(1)
|
(1)
|
5
|
(11)
|
(16)
|
|
Crestor
|
304
|
10
|
14
|
11
|
(18)
|
252
|
15
|
18
|
10
|
4
|
2
|
31
|
(6)
|
-
|
|
Seloken/Toprol-XL
|
150
|
(2)
|
1
|
-
|
n/m
|
145
|
(3)
|
1
|
4
|
n/m
|
98
|
1
|
(58)
|
(58)
|
|
Lokelma
|
143
|
40
|
42
|
66
|
28
|
26
|
99
|
n/m
|
25
|
61
|
61
|
26
|
18
|
27
|
|
roxadustat
|
93
|
26
|
25
|
-
|
-
|
93
|
26
|
26
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Andexxa
|
54
|
36
|
38
|
19
|
(4)
|
1
|
n/m
|
n/m
|
20
|
39
|
39
|
14
|
n/m
|
n/m
|
|
Wainua
|
23
|
n/m
|
n/m
|
23
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
120
|
(22)
|
(20)
|
20
|
(57)
|
63
|
3
|
6
|
30
|
(28)
|
(26)
|
7
|
50
|
40
|
|
BioPharmaceuticals: R&I
|
1,830
|
26
|
28
|
852
|
40
|
457
|
8
|
14
|
346
|
30
|
30
|
175
|
13
|
18
|
|
Symbicort
|
705
|
27
|
31
|
289
|
86
|
203
|
4
|
13
|
130
|
5
|
6
|
83
|
2
|
5
|
|
Fasenra
|
436
|
12
|
13
|
271
|
9
|
27
|
41
|
50
|
102
|
19
|
19
|
36
|
1
|
5
|
|
Pulmicort
|
138
|
(6)
|
(4)
|
5
|
7
|
110
|
(8)
|
(5)
|
14
|
10
|
9
|
9
|
(11)
|
(8)
|
|
Breztri
|
266
|
56
|
57
|
142
|
45
|
68
|
62
|
65
|
37
|
98
|
98
|
19
|
61
|
68
|
|
Tezspire
|
68
|
n/m
|
n/m
|
-
|
-
|
3
|
n/m
|
n/m
|
43
|
n/m
|
n/m
|
22
|
n/m
|
n/m
|
|
Saphnelo
|
124
|
63
|
64
|
110
|
55
|
3
|
n/m
|
n/m
|
7
|
n/m
|
n/m
|
4
|
37
|
67
|
|
Airsupra
|
21
|
n/m
|
n/m
|
21
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
72
|
(21)
|
(21)
|
14
|
(54)
|
43
|
(8)
|
(8)
|
13
|
7
|
7
|
2
|
(16)
|
(14)
|
|
BioPharmaceuticals: V&I
|
355
|
59
|
61
|
145
|
n/m
|
37
|
18
|
37
|
108
|
23
|
20
|
65
|
18
|
23
|
|
Synagis
|
93
|
(6)
|
3
|
-
|
n/m
|
37
|
16
|
36
|
13
|
(19)
|
(20)
|
43
|
(15)
|
(9)
|
|
Beyfortus
|
134
|
n/m
|
n/m
|
95
|
n/m
|
-
|
-
|
-
|
39
|
n/m
|
n/m
|
-
|
-
|
-
|
|
FluMist
|
100
|
34
|
31
|
22
|
43
|
-
|
-
|
-
|
56
|
-
|
(3)
|
22
|
n/m
|
n/m
|
|
COVID-19 mAbs
|
28
|
n/m
|
n/m
|
28
|
n/m
|
-
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
-
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Rare Disease
|
2,148
|
9
|
11
|
1,325
|
12
|
174
|
7
|
29
|
395
|
-
|
-
|
254
|
8
|
14
|
|
Ultomiris
|
1,031
|
33
|
35
|
597
|
34
|
26
|
53
|
84
|
238
|
30
|
30
|
170
|
30
|
37
|
|
Soliris
|
606
|
(22)
|
(18)
|
362
|
(14)
|
110
|
(11)
|
14
|
86
|
(47)
|
(47)
|
48
|
(36)
|
(33)
|
|
Strensiq
|
343
|
20
|
21
|
286
|
21
|
8
|
52
|
55
|
25
|
17
|
17
|
24
|
15
|
23
|
|
Koselugo
|
119
|
37
|
39
|
55
|
2
|
25
|
n/m
|
n/m
|
29
|
90
|
94
|
10
|
52
|
62
|
|
Kanuma
|
49
|
10
|
9
|
25
|
11
|
5
|
(27)
|
(29)
|
17
|
27
|
23
|
2
|
1
|
7
|
|
Other medicines
|
265
|
(11)
|
(7)
|
35
|
(3)
|
179
|
(6)
|
-
|
22
|
18
|
16
|
29
|
(45)
|
(41)
|
|
Nexium
|
212
|
(13)
|
(9)
|
30
|
3
|
140
|
(9)
|
(2)
|
14
|
31
|
29
|
28
|
(45)
|
(41)
|
|
Others
|
53
|
-
|
(1)
|
5
|
(28)
|
39
|
7
|
8
|
8
|
(1)
|
(1)
|
1
|
(52)
|
(51)
|
|
Total Product Sales
|
12,947
|
18
|
20
|
5,580
|
23
|
3,388
|
15
|
23
|
2,729
|
20
|
20
|
1,250
|
-
|
5
|
Table 30:
Alliance Revenue
|
|
|
9M 2024
|
9M 2023
|
|
|
|
$m
|
$m
|
|
Enhertu
|
|
1,045
|
741
|
|
Tezspire
|
|
303
|
179
|
|
Beyfortus
|
|
75
|
16
|
|
Other Alliance Revenue
|
|
75
|
68
|
|
Total
|
|
1,498
|
1,004
|
Table 31:
Collaboration Revenue
|
|
|
9M 2024
|
9M 2023
|
|
|
|
$m
|
$m
|
|
Farxiga: sales
milestones
|
|
52
|
28
|
|
Beyfortus: sales
milestones
|
|
56
|
71
|
|
COVID-19 mAbs licence fees
|
|
-
|
180
|
|
Other Collaboration Revenue
|
|
-
|
38
|
|
Total
|
|
108
|
317
|
Table 32:
Other operating income and expense
|
|
|
9M 2024
|
9M 2023
|
|
|
|
$m
|
$m
|
|
brazikumab licence termination funding
|
|
-
|
75
|
|
Divestment of US rights to Pulmicort Flexhaler
|
|
-
|
241
|
|
Update to the contractual relationships
for Beyfortus (nirsevimab)
|
|
-
|
712
|
|
Other
|
|
152
|
205
|
|
Total
|
|
152
|
1,233
|
Other shareholder information
Financial calendar
Announcement of FY and Q4 2024
results: 6 February
2025
Announcement of Q1 2025 results:
29 April 2025
Dividends are normally paid as follows:
First interim:
Announced with the half year results and paid in
September
Second interim: Announced with the full
year results and paid in March
Contacts
For details on how to contact the Investor Relations Team,
please click
here. For Media
contacts, click
here.
Addresses for correspondence
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
|
db@astfinancial.com
|
Trademarks
Trademarks of the AstraZeneca group of companies appear throughout
this document in italics. Medical publications also appear
throughout the document in italics. AstraZeneca, the AstraZeneca
logotype and the AstraZeneca symbol are all trademarks of the
AstraZeneca group of companies. Trademarks of companies other than
AstraZeneca that appear in this document
include: Beyfortus, a trademark of Sanofi Pasteur
Inc.; Enhertu, a trademark of Daiichi
Sankyo; Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd
(depending on geography); Synagis, owned by AstraZeneca or Sobi aka Swedish Orphan
Biovitrum AB (publ). (depending on geography);
and Tezspire, a trademark of Amgen, Inc.
Information on or accessible through AstraZeneca's websites,
including astrazeneca.com,
does not form part of and is not incorporated into this
announcement.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Cautionary statements regarding forward-looking
statements
In order, among other things, to utilise the 'safe harbour'
provisions of the US Private Securities Litigation Reform Act of
1995, AstraZeneca (hereafter 'the Group') provides the following
cautionary statement:
This document contains certain forward-looking statements with
respect to the operations, performance and financial condition of
the Group, including, among other things, statements about expected
revenues, margins, earnings per share or other financial or other
measures. Although the Group believes its expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this document and the Group undertakes no
obligation to update these forward-looking statements. The Group
identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group's
control, include, among other things:
‒ the
risk of failure or delay in delivery of pipeline or launch of
new medicines
‒ the
risk of failure to meet regulatory or ethical requirements for
medicine development or approval
‒ the
risk of failures or delays in the quality or execution of the
Group's commercial strategies
‒ the
risk of pricing, affordability, access and
competitive pressures
‒ the
risk of failure to maintain supply of compliant,
quality medicines
‒ the
risk of illegal trade in the
Group's medicines
‒ the
impact of reliance on third-party goods
and services
‒ the
risk of failure in information technology
or cybersecurity
‒ the
risk of failure of critical processes
‒ the
risk of failure to collect and manage data in line with legal and
regulatory requirements and
strategic objectives
‒ the
risk of failure to attract, develop, engage and retain a diverse,
talented and capable workforce
‒ the
risk of failure to meet regulatory or ethical expectations on
environmental impact, including
climate change
‒ the
risk of the safety and efficacy of marketed medicines
being questioned
‒ the
risk of adverse outcome of litigation and/or
governmental investigations
‒ intellectual
property-related risks to the
Group's products
‒ the
risk of failure to achieve strategic plans or meet targets
or expectations
‒ the
risk of failure in financial control or the occurrence
of fraud
‒ the
risk of unexpected deterioration in the Group's
financial position
‒ the
impact that global and/or geopolitical events may have or continue
to have on these risks, on the Group's ability to continue to
mitigate these risks, and on the Group's operations, financial
results or financial condition
Glossary
1L,
2L,
etc
First line, second line, etc
ADC
Antibody drug conjugate
aHUS
Atypical haemolytic uraemic syndrome
AKT
Protein kinase B
AL
amyloidosis
Light chain amyloidosis
ANDA
Abbreviated New Drug Application (US)
ASO
Antisense oligonucleotide
ATTR-CM
Transthyretin-mediated amyloid cardiomyopathy
ATTRv
/ -PN / -CM Hereditary
transthyretin-mediated amyloid / polyneuropathy /
cardiomyopathy
BCMA
B-cell maturation antigen
BRCA
/
m
Breast cancer gene / mutation
BTC
Biliary tract cancer
BTK
Bruton tyrosine kinase
C5
Complement component 5
CAR-T
Chimeric antigen receptor T-cell
cCRT
Concurrent chemoradiotherapy
CD19
A gene expressed in B-cells
CER
Constant exchange rates
CHMP
Committee for Medicinal Products for Human Use (EU)
CI
Confidence interval
CKD
Chronic kidney disease
CLL
Chronic lymphocytic leukaemia
COPD
Chronic obstructive pulmonary disease
COP28 28th
annual United Nations (UN) climate meeting
CRC
Colorectal cancer
CRL
Compete Response Letter
CRPC
Castration-resistant prostate cancer
CSPC
Castration-sensitive prostate cancer
CTLA-4
Cytotoxic T-lymphocyte-associated antigen 4
CVRM
Cardiovascular, Renal and Metabolism
DDR
DNA damage response
DNA
Deoxyribonucleic acid
EBITDA
Earnings before interest, tax, depreciation and
amortisation
EGFR /
m
Epidermal growth factor receptor gene /
mutation
EGPA
Eosinophilic granulomatosis with polyangiitis
EPS
Earnings per share
ER
Estrogen
receptor
ERBB2
v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue 2
gene
EVH
Extravascular haemolysis
FDA
Food and Drug Agency (US)
FDC
Fixed dose combination
FISH
Fluorescence in situ hybridization, as in FISH10+
g
Germline, e.g. gBRCAm
GAAP
Generally Accepted Accounting Principles
GEJ
Gastro oesophageal junction
GI
Gastrointestinal
GLP1
/
-RA
Glucagon-like peptide-1 / receptor agonist
gMG
Generalised myasthenia gravis
HCC
Hepatocellular carcinoma
HER2
/ +/- / low / m Human epidermal growth factor receptor
2 / positive / negative / low level expression / gene
mutant
HF/
pEF / rEF
Heart failure / with preserved ejection fraction / with reduced
ejection fraction
hMPV
Human metapneumovirus
HR
Hazard ratio
HR
/ + /
-
Hormone receptor / positive / negative
HRD
Homologous recombination deficiency
HRR
/
m
Homologous recombination repair gene / mutation
i.m.
Intramuscular injection
i.v.
Intravenous injection
IAS
/
B
International Accounting
Standards / Board
ICS
Inhaled corticosteroid
IFRS
International Financial Reporting Standards
IgAN
Immunoglobulin A neuropathy
IHC
Immunohistochemistry, as in IHC90+, etc
IL-5,
IL-33,
etc
Interleukin-5, Interleukin-33, etc
IP
Intellectual Property
IVIg
Intravenous immune globulin
LABA
Long-acting beta-agonist
LAMA
Long-acting muscarinic-agonist
LS-SCLC
Limited stage small cell lung cancer
LRTD
Lower respiratory tract disease
m
Metastatic, e.g. mBTC , mCRPC, mCSPC
mAb
Monoclonal antibody
MDL
Multidistrict litigation
MET
Mesenchymal epithelial transition
NF1-PN
Neurofibromatosis type 1 with plexiform neurofibromas
n/m
Not meaningful
NMOSD
Neuromyelitis optica spectrum disorder
NRDL
National reimbursement drug list
NSCLC
Non-small cell lung cancer
OECD
Organisation for Economic
Co-operation and Development
OOI
Other operating income
ORR
Overall response rate
OS
Overall survival
PAAGR
Post Alexion Acquisition Group Review
PARP
/ i /
-1sel
Poly ADP ribose polymerase / inhibitor /-1 selective
pCR
Pathologic complete response
PCSK9
Proprotein convertase subtilisin/kexin type 9
PD
Progressive disease
PD-1
Programmed cell death protein 1
PD-L1
Programmed cell death ligand 1
PDUFA
Prescription Drug User Fee Act
PHSSR
Partnership for Health System Sustainability and
Resilience
PFS
Progression free survival
PIK3CA
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
alpha gene
PMDI
Pressure metered dose inhaler
PNH
/
-EVH
Paroxysmal nocturnal haemoglobinuria / with extravascular
haemolysis
PPI
Proton pump inhibitors
PSR
Platinum sensitive relapse
PTEN
Phosphatase and tensin homologue gene
Q3W,
Q4W, etc
Every three weeks, every four weeks, etc
R&D
Research and development
R&I
Respiratory & Immunology
RSV
Respiratory syncytial virus
sBLA
Supplemental biologics license application (US)
SCLC
Small cell lung cancer
s.c.
Subcutaneous injection
SEA
Severe eosinophilic asthma
SEC
Securities Exchange Commission (US)
SG&A
Sales, general and administration
SGLT2
Sodium-glucose cotransporter 2
SLL
Small lymphocytic lymphoma
SMI
Sustainable Markets Initiative
sNDA
Supplemental new drug application
SPA
Share Purchase Agreement
T2D
Type-2 diabetes
TACE
Transarterial chemoembolization
THP
A treatment regimen: docetaxel, trastuzumab and
pertuzumab
TNBC
Triple negative breast cancer
TNF
Tumour necrosis factor
TOP1
Topoisomerase I
TROP2
Trophoblast cell surface antigen 2
USPTO
US Patent and Trademark Office
V&I
Vaccines & Immune Therapies
VBP
Volume-based procurement
VLP
Virus like particle
- End of document -
[1] Constant
exchange rates. The differences between Actual Change and CER
Change are due to foreign exchange movements between periods in
2024 vs. 2023. CER financial measures are not accounted for
according to generally accepted accounting principles (GAAP)
because they remove the effects of currency movements from Reported
results.
[2] Core
financial measures are adjusted to exclude certain items. The
differences between Reported and Core measures are primarily due to
costs relating to the amortisation of intangibles, impairments,
legal settlements and restructuring charges. A full reconciliation
between Reported EPS and Core EPS is provided in Table 11 and Table
12 in the Financial performance section of this
document.
[3] The
calculations for Reported and Core Product Sales Gross Margin
exclude the impact of Alliance Revenue and Collaboration
Revenue.
[4] In
Table 2, the plus and minus symbols denote the directional impact
of the item being discussed, e.g. a '+' symbol next to a comment
related to the R&D expense indicates that the item resulted in
an increase in the R&D spend relative to the prior
year.
[5] Post
Alexion Acquisition Group Review. In conjunction with the
acquisition of Alexion, the Post Alexion Acquisition Group Review
Group initiated a comprehensive review, aimed at integrating
systems, structure and processes, optimising the global footprint
and prioritising resource allocations and investments. These
activities are expected to be substantially complete by the end of
2026.
[6] Income
from disposals of assets and businesses, where the Group does not
retain a significant ongoing economic interest, continue to be
recorded in Other operating income and expense in the Company's
financial statements.
[7] The
presentation of Table 4 has been updated to show Total Revenue by
medicine, by including Alliance Revenue and Collaboration Revenue
within each revenue figure. Previously, this table showed Product
Sales for each medicine and therapy area, and the Company's total
Alliance Revenue and Collaboration Revenue were shown as separate
lines at the bottom of the table.
[8] The
presentation of this table has been updated by removing the
"Acquisition of Alexion" column due to immateriality of items in
this category
[9] Based
on best prevailing assumptions around currency
profiles.
[10] Based
on average daily spot rates 1 Jan 2023 to 31 Dec
2023.
[11] Based
on average daily spot rates 1 Jan 2024 to 30 Sep
2024.
[12] Based
on average daily spot rates 1 Sep 2024 to 30 Sep
2024.
[13] Other
currencies include AUD, BRL, CAD, KRW and RUB.
[14] The
table provides an analysis of year-on-year Product Sales, with
Actual and CER growth rates reflecting year-on-year growth. Due to
rounding, the sum of a number of dollar values and percentages may
not agree to totals.
[15] The
table provides an analysis of year-on-year Product Sales, with
Actual and CER growth rates reflecting year-on-year growth. Due to
rounding, the sum of a number of dollar values and percentages may
not agree to totals.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
12 November 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|